Fractalkine Induces the Expression of Intercellular Adhesion Molecule-1 on CD4+ T-lymphocytes: implications for the immunopathogenesis of Multiple Sclerosis by Blauth, Kevin
 FRACTALKINE INDUCES THE EXPRESSION OF INTERCELLULAR 
ADHESION MOLECULE-1 ON CD4+ T-LYMPHOCYTES: IMPLICATIONS FOR 
THE IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS 
 
 
Kevin Richard Blauth 
 
 
A dissertation submitted to the faculty of the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of Doctorate of 
Philosophy in the Curriculum of Neurobiology 
 
 
Chapel Hill 
2012 
 
Approved by: 
Jay Brenman, PhD 
Silva Markovic-Plese, MD, PhD 
Glenn Matsushima, PhD 
Rick Meeker, PhD 
Jenny Ting, PhD
ii 
 
ABSTRACT 
 
KEVIN RICHARD BLAUTH: Fractalkine Induces the Expression of Intercellular 
Adhesion Molecule-1 on CD4+ T-lymphocytes: implications for the 
immunopathogenesis of Multiple Sclerosis 
(Under the direction of Silva Markovic-Plese) 
 
Fractalkine (CX3CL1) is a chemokine that has been shown to play roles in 
lymphocyte chemotaxis, inflammation, and neuroprotection in central nervous 
system (CNS) diseases.  Here we examined roles for CX3CL1 in CD4+ T-cell 
chemotaxis mediated via their upregulation of adhesion molecule expression as 
well as secretion of inflammatory cytokines involved in the pathogenesis of 
relapsing remitting multiple sclerosis (RRMS).  We found that CX3CL1 
concentrations are elevated in the cerebrospinal fluid (CSF) of RRMS patients, 
and that CX3CL1 increases mRNA expression of IFN-γ and TNF-α, and protein 
secretion of IFN-γ by CD4+ T-cells derived from RRMS patients but not those 
derived from healthy controls (HCs). We also show that blood-derived CD4+T-
cells express increased surface levels of CX3CL1 receptor (CX3CR1) and 
intercellular adhesion molecule (ICAM)-1 in RRMS patients in comparison to 
HCs.  Furthermore, the percentage of CX3CR1+ICAM-1+CD4+ T-cells are 
increased in the CSF of untreated RRMS patients in comparison to their 
peripheral blood samples, and CD4+ T-cells which migrate in-vitro toward a 
CX3CL1 gradient express higher levels of ICAM-1 than CD4+ T-cells that do not 
migrate. Furthermore, we demonstrated that CX3CL1 upregulates ICAM-1 
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expression on the surface of RRMS patient-derived but not HC derived CD4+ T-
cells.  Lastly, we show that CX3CL1 stimulates ICAM-1 expression on myelin-
antigen-specific CD4+ T-cell lines derived from RRMS and healthy donors. These 
results indicate that CX3CL1 may preferentially recruit CX3CR1+ICAM-1+CD4+ T-
cells into the CNS during RRMS development, and may activate CD4+ T-cells to 
express higher levels of ICAM-1, as well as the proinflammatory cytokines IFN-γ 
and TNF-α.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 MS Pathology 
 
The autoimmune response is proposed to play a role in the development 
of MS, whereby myelin-autoreactive CD4+ T helper (TH) cells are activated in 
peripheral circulation (Fig. 1.1 A) and migrate through the permeable blood-brain 
barrier (BBB) into the CNS [1-3] (Fig. 1.1 B).  It is still unclear what triggers CD4+ 
T-cell activation against CNS-specific myelin autoantigens—however, molecular 
mimicry by microbial or viral antigens is one of the proposed mechanism [4]. 
Once inside the CNS, CD4+ T-cells encounter antigen-presenting cells (APCs) 
such as microglia and dendritic cells (DCs) and are reactivated by abundant 
myelin-derived antigens [5-7].  This reactivation leads to the release of 
proinflammatory cytokines which stimulate microglia, increase BBB permeability, 
and induce leukocyte chemotaxis, allowing for rapid accumulation of 
proinflammatory CD4+ and CD8+ T-cells, B-cells, and macrophages in the CNS 
[8] (Fig. 1.1 C).  Following this influx of immune cells into the CNS, demyelinating 
lesions—the hallmark pathological feature of MS—are formed in the brain and 
spinal cord.  Lesions are characterized by myelin loss, axonal damage, and 
astrocytic proliferation [9] (Fig. 1.1 D).  MS typically takes a relapsing remitting 
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(RR) course, in which episodes of clinical disease activity (relapses) are followed 
by clinically silent periods (remissions).  Most patients (~85%) are initially 
diagnosed with RRMS, followed years later by secondary progressive (SP)MS, in 
which disability accumulates over time without periods of remission [10]. 
  
1.2 MS Research 
Early MS Research 
A milestone in the history of MS research was the discovery of myelin in 
1854, by Rudolf Virchow [11].  MS was identified in 1868 by Jean-Martin Charcot, 
who dissected the brain of a patient postmortem, and found lesions that he 
named sclerose en plaques[12].  Charcot’s classification of MS as a distinct 
nosological entity was a landmark achievement in the field of neurology [13-15].  
He was the first physician to correlate the clinical symptoms of MS with detailed 
pathological descriptions of CNS lesions [12, 14, 16]. It was not until 1928, 
however, that oligodendrocytes were identified by Hortega and Penfield as the 
cells responsible for myelination in the CNS [17].  A great body of work 
addressing proper fixation, sectioning, and staining brain tissue preceded this 
discovery: Hortega and Penfield’s work was built upon Golgi and Cajal’s efforts to 
allow for anatomical characterization of the CNS via novel staining and 
microscopy techniques.   
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MS disease subsets 
 The most common subset of MS is RRMS, which is a presenting form of 
disease in 75-80% of MS patients.  RRMS patients experience relapses, 
characterized by acute onset of neurological symptoms.  These periods are often 
accompanied by the presence of gadolinium-enhancing lesions, which denote 
BBB disruption.  MS relapses are manifested by symptoms including motor 
weakness, visual symptoms, sensory deficit, coordination difficulties, or vertigo.  
Relapses can last from days to months, and are abutted by periods of without 
neurological symptoms called remissions [10]. 
 Most RRMS patients eventually develop SPMS.  SPMS is characterized 
by progressive neurological impairment with no relapses and remissions, CNS 
atrophy, and less inflammation than is observed in RRMS.  Some MS patients 
exhibit a progressive disease course from the onset of the disease, with no 
relapses and remissions, and these patients are diagnosed with PPMS. It is 
unclear at this time whether these ―subsets‖ of MS are truly variations of the 
same disease, as they are presently classified, or if in fact these subsets 
represent distinct diseases with unique underlying causes.  To this point, 
neuromyelitis optica (NMO), which was until recently considered to be a subset of 
MS, is now recognized as a distinct CNS autoimmune disease in which 
aquaporin-4 water channels expressed on astrocytes are targeted by NMO IgG 
antibodies, ultimately leading to demyelination of the optic nerve and spinal cord 
[18]. 
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Environmental Studies 
It is broadly accepted that both environmental and genetic factors play 
roles in the pathogenesis of MS.  Epidemiological studies have verified that 
several environmental factors may trigger MS clinical presentation.  These 
include geographical latitude, vitamin D deficiency [19], smoking [20, 21], and 
perhaps CNS infection with viruses such as Epstein-Barr virus (EBV) [22, 23] or 
varicella-zoster virus (VZV) [24].  Environmental studies have broadly given 
credence to the hypothesis that MS is not only determined by a genetic 
susceptibility, but is a disease in which individuals of a genetically-susceptible 
background are exposed to environmental agents that instigate the pathogenesis 
of MS. The hygiene hypothesis is based on epidemiological evidence that higher 
incidence of autoimmune diseases in the developed world may be due to lower 
exposure rates to infection and better sanitation [25].  A reduced exposure to 
helminthes has been targeted by some researchers as a potential cause of MS 
development, because helminthes shift the immunological balance toward a more 
immunosuppressive state.  Specifically, helminthes may induce T-cell populations 
such as CD4+CD25+FoxP3+ T regulatory cells that prevent the development of 
autoreactive pathogenic T-cells such as Th17 cells and Th1 cells, and instead 
produce a Th2 response [26]. 
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MS Genetics 
Genetic factors clearly play a role in MS pathogenesis.  Clues of genetic 
susceptibility to MS include studies which show that people of Caucasian descent 
are at greater risk to develop MS than other groups [27], and that familial 
recurrence is common among MS sufferers [28].   More recently, large multi-
center collaborative studies revealed that the HLA class II extended haplotype 
HLA-DRB5*0101-HLADRB11501-HLA-DQA1*0102-HLA-DQB1*0602 confers the 
majority of genetic susceptibility to MS [29].  Other immunologically-related 
genetic targets have been identified as potentially related to MS susceptibility as 
well, including genetic variants of the gene icam1 [30], and immune targets such 
as IL2RA, IL7R and CD58 [29].  Two single nucleotide polymorphisms (SNPs) in 
CX3CL1 receptor (CX3CR1) have been shown to alter CX3CR1 expression 
levels and binding affinity for CX3CL1 [31, 32].  These SNPs are V249I and T280M.  
Combinations of the expression of these SNPs lead to four CX3CR1 haplotypes: 
V249T280, I249T280, I249M280, and V249M280 [33].  While MS susceptibility has not 
been found to be associated with expression of any of these haplotypes, severity 
of MS course has been found to be correlated with haplotype expression [34].  
I249T280 was found to be expressed in a significantly greater number of RRMS 
patients than in SPMS patients.   This suggests that RRMS patients who express 
this haplotype do not progress to SPMS as quickly as patients who express the 
other haplotypes, suggesting a potential protective effect for CX3CR1 haplotype 
I249T280 [34].  In summary, human genetic research has proven to be valuable in 
uncovering specific molecular targets which confer MS susceptibility and may be 
useful in the future for earlier and more accurate MS diagnosis. 
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Antigen-specific CD4+ T-cells. 
MS was first proposed to be a disease brought on by self-reactive CD4+ T-
cells due to experimental autoimmune encephalomyelitis (EAE) studies which 
showed that CNS demyelination in EAE can be induced by immunization with 
CNS myelin proteins. Myelin basic protein (MBP) and PLP are the most 
extensively studied CNS myelin proteins in the context of EAE, and reactivity to 
these antigens is proposed to be a component of MS immunopathogenesis as 
well [35, 36].  Autoreactive MBP and PLP-reactive T-cells are present in similar 
frequencies in patients and controls [1, 37, 38]. However, Zhang and colleagues 
showed that MBP- and PLP-reactive CD4+ T-cells derived from the CSF and 
blood of RRMS patients more frequently express IL-2R activation marker, so that 
their activation state and not their mere presence constitutes a hallmark of the 
autoimmune response in MS [39].  Taken together, these data suggest that while 
both HCs and MS patients have circulating myelin-protein autoreactive T-cells, in 
MS patients they have already been repeatedly activated by myelin protein 
antigens in-vivo. 
 
Immunological Studies 
A large body of data derived from human research points to an 
immunological basis of MS.  The immunological etiology of MS is closely tied to 
MS genetics, as the HLA class II haplotype associated with MS susceptibility 
codes for Major Histocompatibility Complex II (MHC II), a heterodimer expressed 
on lymphocytes, and APCs that present antigen to CD4+ T-cells to trigger 
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immune response [29].  While myelin-reactive T-cells are found in circulation of 
both MS patients and HCs, those derived from MS patients express activated 
phenotype, and do not require costimulatory CD28 signaling for recurrent 
activations [40, 41]. [39].  Importantly, myelin-reactive CD4+ and CD8+ T-cells 
from MS patients express a distinct inflammatory cytokine profile, expressing 
increased levels of IFN-γ [42].  Also, myelin oligodendrocyte glycoprotein 
MOG97-109 reactive CD4
+ T-cells have been shown to be present in greater 
frequencies in the blood of MS patients compared to HCs [43]. 
 It is well-established that CD4+, CD8+ T-cells, B-cells and monocyte-
derived cells are implicated in the pathogenesis of MS [2, 44-47].  These cell 
subsets play role in the immunosurveillance of the CNS in health and disease, 
and in MS lesion formation [48] (Fig. 1.1).  In this study, we will evaluate these 
cell subsets derived from RRMS patients and HCs for differences in surface 
expression of chemokine receptors and adhesion molecules. The following is a 
brief overview regarding the role of these cell subsets in MS. 
CD4+ T-cells. Adoptive transfer of activated myelin-specific CD4+ T-cells 
into wild type mice induce EAE, suggesting that CD4+ T-cells are the prime 
pathogenic cells in EAE and MS [49, 50].  Specifically, TH1 and TH17 CD4
+ T-cell 
subsets mediate disease development in multiple EAE models [51-53].  Genetic 
studies of MS have implicated CD4+ T-cells in the development of the disease: 
expression of DR2 HLA class II alleles which are involved in antigen presentation 
to CD4+ cells are associated with MS susceptibility [29, 54].  Therefore, the 
expression of proteins related to CD4+ T-cell migration into the CNS—chemokine 
receptors and adhesion molecules—are of great interest. 
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 CD8+ T-cells.  CD8+ T-cells’ role in MS pathogenesis have not been 
studied as thoroughly as the role of CD4+ T-cells.  However, MS genetic studies 
implicate CD8+ T-cells as the susceptibility for the disease is associated with the 
expression of MHC class I allele HLA-A*301, and upregulation of MHC class I 
molecules has been observed in MS lesions [55].  Clonally-expanded CD8+ T-
cells are present in the perivascular regions and at the lesion edge [44, 45].  
Furthermore, CD8+ T-cells are present in greater numbers in active MS lesions 
than CD4+ T-cells [44, 56].  Myelin-specific CD8+ T-cells have been derived from 
the blood of MS patients and HCs [57], and these cells have been shown to 
express IFN-γ and TNF-α, and have the ability to lyse oligodendrocytes in vitro 
[58]. 
CD19+ B-cells.  B-cell involvement in MS has been historically 
understudied, but has recently become a major focus in MS research.  As early 
as 1947, Kabat, et al., have suggested that myelin protein-specific antibodies 
may play role in human demyelinating disease [59].  Oligoclonal bands 
representing clonal IgG in the CSF of MS patients are considered a contributing 
finding for the diagnosis of MS [60], and several studies have demonstrated that 
antibodies are present in the demyelinated areas of the brain and in the CSF of 
MS patients [61, 62].  Autoantibodies against MOG, MBP, and proteolipid protein 
(PLP) have been identified in MS lesions, and proposed to contribute to MS 
pathogenesis [63-66].  These myelin-reactive autoantibodies are proposed to 
play a role in MS by several mechanisms, including antibody-dependent cellular 
cytotoxicity (ADCC) [67], opsonization and phagocytosis[63], complement 
activation of effector cells, or antibody-induced demyelination [68].  Heightened 
levels of complement deposition, which support the functions of pathogenic 
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antibodies, have also been observed in MS lesions. Rituximab, a monoclonal 
antibody against CD20 that specifically lyses B-cells, has been shown to reduce 
gadolinium-enhancing lesions and relapse rates at early time point, implicating 
the role of B-cells in the antigen presentation or the inflammatory response 
regulation, and not only antibody production [47]. Importantly, in an EAE model, 
B-cells were required to induce an immune response to CNS myelin proteins [69].  
B-cell migration across BBB endothelia has been shown to be dependent upon 
chemokines, including CCL2 [70]. 
 CD14+ monocytes.  Monocytes act as APCs in peripheral circulation and in 
the lymphoid organs, and also migrate into the CNS where they differentiate into 
DCs and macrophages [71].  In EAE, monocytes-derived macrophages 
participate in the disease pathogenesis by migrating across the BBB, and actively 
participate in demyelination by digesting the myelin sheath surrounding axons 
[72].  The ablation of monocyte recruitment into the CNS blocks lesion formation 
in EAE [73].  Notably, CCL2 blockade during EAE has been shown to block 
pathogenesis of the disease [74]. One feature that characterizes active MS 
lesions is the presence of macrophages containing myelin degradation products 
[75].  Monocyte-derived macrophages may also act as APCs in CNS lesions, 
expressing MHC class II molecules and presenting myelin-Ag products such as α 
B-crystallin that may reactivate infiltrating CD4+ T-cells [76]. 
 
Several other immune cell subsets also play roles in MS.  A brief 
description of two of these subsets is as follows: 
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Regulatory T cells. In 1977, Adda, et al. showed that ―suppressor cells‖ 
are increased in number during EAE recovery [77]. Since then, FoxP3+ 
Regulatory T cells (Tregs) have been shown to play role in MS. Tregs can restrict 
proliferation and cytokine production of immune cells including CD4+ T cells, 
CD8+ T cells, B cells, monocytes, macrophages, and DCs.  Tregs play an 
important role in the control of peripheral tolerance, and the breakdown of 
tolerance to self-reactive antigens may lead to autoimmune diseases such as MS 
[78].  Tolerance in MS may be broken by a reduction in total Treg numbers, by 
the existence of dysfunctional Tregs in individuals susceptible to MS, and 
inhibition of T-cell suppression by Tregs [79] [80].  Interestingly, Tregs have been 
found to be increased in numbers due to administration of immunomodulatory 
therapies IFN-β and glatiramer acetate, further suggesting a protective role for 
Tregs [81, 82]. 
Dendritic cells.  DCs are APCs that process and present antigens to T 
cells and secrete regulatory cytokines that are capable of inducing the activation 
and differentiation of naive and memory T cells.  Peripheral blood DCs have been 
shown to be able to migrate to the CNS [83], and DCs are also found in the CSF 
and lesions of MS patients [84-86].  In EAE, T cells and DCs interact in the CNS 
to drive disease pathogenesis [5, 87, 88].  Analyses of MS CNS tissue have 
shown that perivascular spaces on the border of active lesions contain a 
substantially greater DC content than NAWM [84].  This suggests that DCs may 
play a role in antigen presentation at the BBB, and therefore may play a primary 
role in MS pathogenesis.  Recent studies have also shown that DCs play 
important roles in secretion of proinflammatory cytokines that induce Th17 cell 
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differentiation [83]; this polarization can be blocked by IFN-β1a [89], as well as 
simvastatin [90]. 
 
Biomarker Identification Studies 
Early diagnosis and treatment may improve clinical outcome for MS 
patients [91].  However, there is currently no single test which can diagnose MS, 
so in many MS patients the initiation of disease-modifying treatments is delayed 
[92].  CSF samples are typically available at the time of MS diagnosis, and 
therefore MS disease activity biomarkers in the CSF would be of great benefit for 
the improvement of diagnostic accuracy and the timely initiation of the treatment 
of MS.  Several potential biomarkers have been identified which may aid in the 
diagnosis of MS, or prognosis to determine MS disease course.  Potential CSF 
biomarkers include adhesion molecules such as soluble Vascular Adhesion 
Molecule-1 (sVCAM-1) [93-95], sICAM-1 [96], and Neural Cell Adhesion Molecule 
(NCAM) [94, 95], as well as chemokines such as CXCL9, CXCL10, CXCL13, 
CCL5 [97, 98]. 
 
CSF-derived Cell Analysis in MS 
T-cells are the predominant lymphocyte subset derived from MS CSF [99-
101].     A greater percentage of CSF-derived T-cells are activated in comparison 
to the blood-derived T-cells, particularly during relapses of the disease [102].  
The analysis of chemokine receptor surface levels on the CSF-derived CD4+ T-
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cells has revealed that several chemokine receptors (CCR5, CXCR3) are 
upregulated significantly on these cells, correlating with upregulation of these 
receptors on lesion-derived CD4+ T-cells [98]. 
 
Animal Models of MS  
Animal models of MS have served as tools to understand the genetic and 
molecular mechanisms of MS pathology and have been instrumental in 
developing several effective MS therapies.  Three animal models have been 
widely used to study MS: EAE, chemically-induced demyelination such as 
cuprizone-induced demyelination, and virally-induced chronic demyelination.  In 
the following subsections, we will briefly discuss each MS animal model and its 
contribution to our understanding of MS. 
 
EAE 
Thomas Rivers characterized EAE in 1933 [103].  It was not until a decade 
later, however, that it was observed that the neurological damage induced in EAE 
is pathologically similar to human CNS demyelinating disorders [104].  In classic 
EAE, a mouse or other mammalian recipient is immunized with CNS myelin 
antigen, or disease is elicited via passive transfer of encephalitogenic T-cells [59, 
105].  In these models, a TH1 cell-mediated immune response at the spinal cord 
and brain leads to CNS demyelination [104].  This myelin damage results in 
clinical manifestations similar to those seen in MS, such as sensory deficits, 
motor weakness, visual loss or coordination deficits [35].  Research in EAE has 
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led to a wealth of data pertaining to MS, and insights attained from these models 
have led to the development of disease-modifying therapies for MS [106, 107].  
Largely due to research in EAE animal models, the immune-initiated disease 
hypothesis of MS has been favored by the majority of MS researchers.  In this 
model, myelin autoreactive T-cells enter the CNS and induce focal inflammatory 
demyelination of the brain and spinal cord, causing acute and chronic disability in 
MS patients.  EAE has several drawbacks, however.  First, in B6 mice, EAE 
affects the lumbar spinal cord, while the brain is predominantly affected in MS 
[108].  Second, EAE does not recreate the MS pathological profile in its entirety; 
for instance, classic EAE does not mirror B-cell autoantibody production 
adequately [109].  Third, Lastly, therapies that have been shown to be effective 
for the treatment of EAE have often not been shown to be effective for the 
treatment of MS [110]. 
Additional findings from the EAE model show that adhesion molecules 
such as ICAM-1 are upregulated on the luminal side of endothelial cells of the 
BBB [111, 112], and facilitate autoreactive cell entry into the CNS (Fig. 1.1 B).  
ICAM-1 expression on T-cells is also critical for EAE development [111], and 
CX3CR1 has been shown to be critical for the transmigration of NK-cells into the 
CNS during EAE [113]. 
 
The Cuprizone intoxication Model of Demyelination and Remyelination 
Several models of demyelination utilize a drug or toxin to induce 
demyelination.  These models include lysolecithin injections, which induce 
demyelination via activation of phospholipase A2 [114], ethidium bromide 
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injections into the spinal cord [115], and introduction of cuprizone in the diet 
[116].  Of these models, cuprizone-induced demyelination is the most widely 
used toxin-induced demyelination model in MS research.  In the late 1960s, 
studies by William Carlton established that ingestion of the copper chelator 
cuprizone has neurotoxic effects [117, 118].  It was later found that mature 
oligodendrocytes are particularly susceptible for apoptosis in the presence of 
cuprizone, while other cell types are not affected [119].  Samuel Ludwin then 
characterized cuprizone-induced demyelination in the superior cerebellar 
peduncle, finding that axons remained undamaged while demyelination and later 
oligodendrocyte death occurred [120].  After removal of cuprizone from the diet, 
remyelination was found to progress quickly, remyelinating axons to roughly half 
the thickness of undamaged myelinated fibers [120].  Ludwin then studied the 
source of remyelinating oligodendrocytes during remyelination, finding that 
immature, proliferating oligodendrocytes differentiated into mature 
oligodendrocytes, which were ultimately responsible for remyelination of 
cuprizone-demyelinated axons [121]. 
Demyelination by cuprizone represents an attractive model to study 
demyelination and remyelination because cuprizone-induced demyelination holds 
to a predictable time course in which complete demyelination of several brain 
regions, including the corpus callosum and cerebellar peduncle, occurs over 
several weeks of cuprizone ingestion [122].  If this period of damage is followed 
by removal of cuprizone from the diet, subsequent robust remyelination is 
consistently observed [119, 122].  The extent of demyelination, remyelination, 
and infiltration of damaged areas by macrophages and migroglia can be scored 
by Luxol-Fast blue (LFB) staining for myelin and Periodic Acid Schiff (PAS) 
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staining for macrophages and microglia [123].  One drawback of the cuprizone 
model is that it does not feature infiltration of peripheral immune cells that is a 
part of MS pathogenesis.  However, the cuprizone model of demyelination has 
been optimized in several strains of mice, including C57/B6, as this background 
features an abundance of transgenic and knockout lines pertinent to MS 
pathogenesis [116].  Because of the reproducibility of this model, it is useful tool 
to study the effects of therapies to suppress demyelination, and is especially 
valuable in evaluating therapies that may enhance remyelination [124].  In recent 
years, the cuprizone model of demyelination has been utilized to uncover the 
importance of insulin-like growth factor-1 (IGF-1) in protection of mature 
oligodendrocytes from apoptosis during demyelination [125], whose upregulation 
may be induced in microglia, macrophages, and astrocytes by IL-1β in to promote 
remyelination [126].  This model has also been utilized to uncover roles for 
chemokines such as MIP-1α in recruitment of microglia to areas of damage and 
upregulation of TNF-α during demyelination [124], as well as a previously 
unknown role for TNF-α interactions with TNFR2 in oligodendroctye regeneration 
after a demyelinating event [127]. 
 
 
Virus-induced Demyelination 
Potential roles for viruses in MS have historically been studied and 
intensely debated.  Many researchers currently believe that MS may be virally-
induced, perhaps via molecular mimicry, leading to an autoimmune response to 
CNS myelin proteins in genetically-susceptible individuals.  Others believe that a 
single, yet-unidentified virus may be responsible for MS pathology, evidenced by 
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the persistent presence of oligoclonal banding in CSF derived from MS patients 
[128].  Several viral models of demyelination have been developed; the most 
commonly used is Theiler’s murine encephalomyelitis virus (TMEV).  TMEV 
presents a model which recapitulates several features of MS: (1) presence of 
CNS lesions, (2) the triggering of an autoimmune response via the CNS viral 
infection (3) the presence of inflammatory cells in and around lesions during 
myelin destruction, and (4) several features of MRI results in mice that are similar 
to human MS MRIs, including the presence of brain, brainstem, and spinal cord 
lesions, and T2 hyperintense spinal cord lesions [129].  
Mechanisms of Myelin destruction and lesion formation 
 Four distinct patterns of lesions have been identified in CNS tissue derived 
from MS patients biopsies by Lucchinetti, et al.  The four distinct patterns of 
lesions are as follows [130]: 
Pattern I: The lesion infiltrate is composed predominately of CD3+ T-
lymphocytes and macrophages.  Demyelination is found in a perivenous pattern, 
and there is a sharp distinction between the lesion edge and neighboring tissue.  
Oligodendrocytes are present in higher numbers than in lesion patterns III and IV. 
Pattern II: Similar to pattern I, pattern II lesions are largely composed of 
CD3+ T-lymphocytes and macrophages.  However, pattern II lesions also feature 
high levels of IgG, and complement C9neo antigen.  Ig reactivity in pattern II 
lesions was associated with degenerating myelin at the active plaque edge and 
with degenerating myelin products within lesional macrophages.  A perivenous 
pattern of demyelination is noted, and there is a sharp distinction between the 
lesion edge and neighboring tissue.  Oligodendrocytes are present in similar 
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numbers to pattern I lesions, and higher numbers than in lesion patterns III and 
IV. The presence of shadow plaques indicates that some remyelination has 
occurred. 
Pattern III: The infiltrate in these lesions is composed of CD3+ T-
lymphocytes and macrophages.  The edge between the lesion and surrounding 
tissue is not sharply defined, but rather is ill-defined, and in about one-third of 
pattern III lesions, a concentric shape is observed.  Importantly, oligodendrocyte 
dystrophy was observed throughout this lesion type as measured by loss of 
myelin-associated glycoprotein (MAG) and by oligodendrocyte apoptosis.  The 
oligodendrocyte destruction in this lesion pattern was similar to that seen in toxin- 
or virus-induced animal models of MS. 
Pattern IV: Macrophages compose a larger proportion of total infiltrate in 
this subset, while a significant CD3+ T-lymphocyte presence is also observed.  
Oligodendrocyte cell death was observed in a small ring of periplaque white 
matter as measured by DNA fragmentation: no shadow plaques were observed, 
and remyelination appeared to be absent. Similar to pattern III, the 
oligodendrocyte destruction in this lesion pattern was similar to that seen in toxin- 
or virus-induced animal models of MS.  This lesion subset was found exclusively 
in patients with PPMS.  
 Interestingly, these four lesion pattern subsets were found to be 
homogeneous within an individual patient [130].  However, these findings are still 
somewhat controversial because another group has found that all acute MS 
lesions display complement activation and oligodendrocyte apoptosis, while 
subacute lesions derived from the same patients display complement activation 
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but no signs of oligodendrocyte apoptosis [131].  This was interpreted as 
evidence that oligodendrocyte apoptosis is a hallmark of the earliest stage of MS 
lesion formation [131]. 
 Henderson, et al., attempted to address mechanisms of myelin destruction 
in MS by analyzing immune cell infiltrate in active lesions derived from patients 
with early MS [84].  This group found that the normal appearing white matter 
(NAWM) surrounding newly formed lesions contained an abundance of activated 
microglia that expressed CD45 and MHC Class II compared with lower numbers 
of microglia in NAWM that was not near lesion tissue [84].  NAWM also contained 
astrocytes, neurons, and oligodendrocytes that expressed IgG.  Prephagocytic 
tissue (defined in this study as still-intact tissue exhibiting signs of impending 
myelin damage) directly adjacent to actively demyelinating lesions was found to 
contain damaged and apoptotic oligodendrocytes, and only a slight increase in T 
cells compared to NAWM [84].  In phagocytic lesion tissue, IgG+ phagocytic MHC 
Class II-negative microglia containing myelin products were found in abundance 
compared to in NAWM.  This group speculated that microglia in phagocytic lesion 
tissue may expand active MS lesions by secreting molecules toxic to 
oligodendrocytes, or that active lesions may expand due to hypoxic stress in 
oligodendrocytes.  Interestingly, CD4- and CD8+ T-cells were not found at greatly 
heightened levels in phagocytic tissue, but were found in high levels in 
perivascular prephagocytic tissue [84].  In recently demyelinated tissue, 
demyelinated axons were found in close proximity to IgG+ activated microglia 
and macrophages.  CD4- and CD8+ T-cells, B-cells, and IgG-producing plasma 
cells were found in this tissue in greater numbers than in phagocytic tissue, and 
regenerating oligodendrocytes were also observed [84]. 
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1.3 The Role of CX3CL1 and CX3CR1 in CNS Inflammatory Diseases 
Chemokines facilitate the chemotaxis of proinflammatory leukocytes 
toward areas of inflammation and activate adhesion molecules to bind their 
receptors, enabling cell migration and transmigration [132, 133].  In experiments 
relevant to the study of MS, several groups have characterized various 
chemokine and chemokine receptor knockout mice, allowing analysis of 
chemokine function in vivo [113, 134, 135].  A broad conclusion drawn from these 
studies is that chemokines direct migration and extravasation of leukocytes into 
the CNS during inflammation.  Experiments utilizing EAE have shown that robust 
upregulation of a variety of chemokines and chemokine receptors occurs in 
concert with disability accumulation and demyelination [72], and chemokines and 
chemokine receptors have been shown to be critical for EAE development [136].  
Because of convincing temporal and spatial correlations between chemokine 
expression and CNS leukocyte infiltrate in EAE, chemokines have become a 
major focus of MS research [72, 137, 138]. 
Chemokines and chemokine receptors play multiple roles MS.  Levels of 
several chemokines, including CXCL9, CXCL10, CXCL13, CCL5, and CX3CL1 
are enhanced in the CSF of MS patients during acute attacks of inflammatory 
demyelination in comparison to the CSF derived from healthy controls (HCs) or 
neurological disease controls [97, 98, 139].  A higher percentage of CSF-derived 
leukocytes express chemokine receptors, including CCR5, CXCR3, and CCR7 
during acute MS exacerbations, suggesting functional significance of elevated 
chemokine levels observed in the CSF [98, 100, 140].  Robust expression of 
multiple chemokine receptors has been observed on the surface of leukocytes in 
the demyelinating lesions of RRMS patients, suggesting that chemokine 
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receptors may allow inflammatory cells to hone to lesions [139, 141, 142].  
Expression of CX3CR1 has been observed on the surface of leukocytes in the 
demyelinating lesions of relapsing remitting (RR) MS patients, indicating that 
CX3CR1 may guide inflammatory cells to lesions [139]. 
In 1997, Bazan and colleagues identified CX3CL1, noting that unlike all 
other known chemokines, the sequence for CX3CL1 does not terminate at the 
end of the chemokine domain (76 aa).  Rather, the CX3CL1 chemokine domain is 
connected to a mucin stalk (241 aa), followed by a transmembrane domain (18 
aa) and an intracellular domain (37 aa) [143].  This group found that, when 
expressed in HEK293 cells, soluble CX3CL1 is shed as a 95 KDa glycoprotein 
[143].  Later, Pan and colleagues noted that CX3CL1 mRNA is expressed 
predominantly in the healthy murine brain [144].  Later in 1997, Imai and 
colleagues identified CX3CR1, a high affinity functional CX3CL1 receptor that 
was shown to mediate cell adhesion and transendothelial migration of T-cells and 
monocytes [145].  CX3CR1 had been previously identified as ―orphan‖ receptor 
chemokine β receptor-like 1 (CMKBRL1) by Combadiere and colleagues [146].  
CX3CR1 is a seven-transmembrane, G-Protein-coupled receptor [145]. 
CX3CL1 is the only member of the δ-chemokine family, distinguished from 
other members of the chemokine superfamily by 1) a distinct structural motif in 
the N-terminus [143] and 2) duality as a membrane-bound form, in which it acts 
as an adhesion molecule, and a soluble form, in which it mediates immune cell 
migration.  Membrane-bound CX3CL1 is cleaved constitutively by disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10) to produce baseline 
levels of soluble CX3CL1 (Table 1.1).  During inflammation, activated cells 
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produce disintegrin and metallopeptidase domain-containing protein 17 
(ADAM17) to enhance the production of soluble CX3CL1 [147-149] (Table 1.1).  
The cleavage of CX3CL1 by these two matrix metallaproteinases (MMPs) is 
intriguing for several reasons.  First, the ADAM 10—ADAM 17 system of 
cleavage of membrane-bound CX3CL1 allows for immediate soluble CX3CL1 
production in response to an inflammatory extracellular microenvironment.  
Second, MMPs have recently come into focus as potential therapeutic targets in 
neuroinflammatory diseases such as MS [150], and ADAM17 and ADAM10 levels 
have specifically been shown to be upregulated in chronic active MS lesions 
[151].  Last, ADAM17 is known to cleave several cytokine receptors and 
membrane-bound adhesion molecules, which are intricately involved in 
neuroinflammation, such as IL-6R, TNF-α, and ICAM-1 [152-155]. 
 
CX3CL1 and its Downstream Signaling Pathways 
Molecular pathways downstream of CX3CL1 vary between different cell 
subsets.  In CD14+ monocytes, co-culture with CX3CL1-expressing human 
umbilical vein epithelial cells (HUVECs) leads to up-regulation of IL-6, CCL2, and 
MMP-9 [156].  In murine microglia, however, CX3CL1 suppresses production of 
IL-6, NO, and TNF-α, [157] (Table 1.1).  Application of CX3CL1 in-vitro 
suppresses neuronal cell death by activated microglia [157] (Table 1.1).  This 
discrepancy between molecular pathways induced by membrane-bound and 
soluble CX3CL1 may underlie distinct molecular actions by these two isoforms, or 
may indicate cell subtype specific actions of CX3CL1.  
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CX3CR1 Surface Expression is Modulated by Several Cytokines and 
Chemokines 
CX3CR1 expression is upregulated by several cytokines and chemokines, 
and it is dependent upon cell type.  IL-2 upregulates expression of CX3CR1 via 
NFAT2, while IL-15 down-regulates CX3CR1 expression via NFAT1 in peripheral 
blood mononuclear cells (PBMCs) [158] (Table 1.1).  In human monocytes, 
CCL2-CCR2 interactions were shown to stimulate surface expression of CX3CR1 
[159] (Table 1.1).  In a recent study involving human monocytes, IL-10 was 
shown to upregulate surface expression of CX3CR1 via phosphatidylinositol 3-
kinase (PI3K); conversely, IFN-γ decreased surface expression of CX3CR1 [160] 
(Table 1.1).  In contrast, in HUVECs, the effect of IFN-γ incubation was an 
increase in CX3CR1 expression [161] (Table 1.1).  Furthermore, sIL-6R signals 
through gp130 in HUVECs to inhibit the IL-1 or IFN-γ-induced CX3CR1 
expression [162] (Table 1.1).  These findings indicate that regulation of CX3CR1 
surface expression involves several cytokines and is dependent upon cell type.  
This specificity of CX3CR1 surface expression modulation per cell subset may 
provide a therapeutic opportunity to modify the expression of CX3CR1 on specific 
cell types.  
 
CX3CR1 and its Downstream Signaling Pathways 
CX3CR1 is a G-protein-coupled receptor that is responsible for 
intracellular signaling via several pathways.  Expression of CX3CR1 mRNA is 
down-regulated in response to Receptor Activator of Nuclear Factor Kappa B 
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Ligand (RANKL) in a monocyte-like cell line, inhibiting chemotaxis [163] (Table 
1.1).  In human pulmonary artery endothelial cells (HPAECs) and HUVECs, 
CX3CL1 signals through CX3CR1 to increase surface ICAM-1 via the JAK2-
STAT5 pathway, thereby promoting adhesion of neutrophils [164] (Table 1.1).  In 
rat hippocampal neurons expressing CX3CR1, application of CX3CL1 induces 
antiapoptotic pathways via PI3K-Akt pathway, resulting in neuroprotection [165].   
 
Potential Roles for CX3CL1-CX3CR1 in CNS Inflammatory Diseases 
In humans, membrane-bound CX3CL1 is highly expressed on neurons 
and at lower levels on microglia, macrophages, astrocytes, endothelial cells, and 
lymphocytes.  Within the CNS, neurons produce far more CX3CL1 than any other 
cell subset.  Furthermore, CX3CL1 has been shown to function as a 
neuroprotectant by inhibition of Fas-mediated microglial apoptosis [166].  In 
several mouse models of CNS disease, CX3CL1-CX3CR1 interaction has been 
shown to be critical for effective microglial responses to inflammatory and 
neurotoxic stimuli, and in the absence of CX3CR1, microglia undergo cell-
autonomous neurotoxicity [167].  In human mononuclear cells, CX3CR1 is 
expressed on monocytes, macrophages, microglia, CD4+ T-cells, CD8+ T-cells, 
DCs, and NK-cells [145, 168].  In monocytes, surface expression of CX3CR1 is 
increased by CCL2 via p38 MAPK, and this up-regulation enhances the binding 
of fractalkine to monocytes [159].   
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Neuroprotective Effects of CX3CL1-CX3CR1 Interaction may Contribute to the 
Attenuation of CNS Lesion Formation in MS 
CX3CR1 is expressed in astrocytes and microglia in MS lesions, as well 
as in astrocytes of the NAWM surrounding MS lesions [169].  CX3CR1 has been 
shown previously to be expressed on 8% of CD4+ T-cells derived from HCs [170], 
and Foussat and colleagues have reported that CX3CR1 expression is 
significantly higher in CD4+CD45RO+ memory T-cells in comparison to the naïve 
T-cells[170].  CX3CR1 surface expression is stimulated by CCL2 which induces 
surface expression of CX3CR1 in monocytes [159].  Chemotaxis assays 
performed in-vitro have demonstrated that a significantly greater percentage of 
CD4+CD45RO+ cells migrate toward CX3CL1 in comparison to the naïve T-
cells[170]. 
In EAE, CX3CL1 has been demonstrated to selectively recruit NK-cells 
into the CNS.  CX3CR1 KO mice, in which NK-cell migration is impaired, 
demonstrate increased EAE severity, lesion volume, and higher mortality [113], 
likely due to a regulatory role of NK-cells in CNS demyelinating disorders.  While 
a role for CX3CL1 in ICAM-1 up-regulation has not been studied in leukocytes, 
CX3CL1 has been shown to increase expression of ICAM-1 in vascular 
endothelial cells via CX3CR1 and Jak2-Stat5 signaling [164].  Levels of 
phosphorylated Jak2 and Stat5 were increased in sequential order within 30 
minutes of exposure to CX3CL1; an effect which was blocked by transfection of 
CX3CR1 siRNA [164].  This increase of ICAM-1 expression via CX3CL1-
CX3CR1 interactions resulted in firmer adhesion of neutrophils to endothelial 
cells [164]. 
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CX3CL1-CX3CR1 interactions are well-studied in regard to their functions 
in transendothelial migration. For transendothelial migration to occur, a leukocyte 
follows a series of steps: first, it tethers to the endothelial cell surface; then it rolls, 
and firmly adheres to the surface; lastly, it migrates between the tight junctions of 
the endothelial barrier [171].  CX3CL1 cleaved from the surface of BBB 
endothelial cells contributes to this process by attracting CX3CR1-expressing 
leukocytes [143, 145], and CX3CL1 expressed on the BBB cell surface may help 
mediate firm adhesion of leukocytes to endothelial cells [172].  However, it is 
unclear whether CX3CL1-CX3CR1 interactions are critical for the migration of 
immune cells into the CNS during MS lesion development. 
Recently Broux, et al., found that CX3CR1 is a marker for CD4+CD28- T-
cells, and that this cell subset is expanded in a subgroup of MS patients [139].  
Interestingly, this subset of cells expressed high levels of adhesion molecules 
such as LFA-1, ICAM-1, and VLA-4.  MS patients exhibited higher levels of 
ICAM-1 expression on CD4+CD28-CX3CR1+ T-cells than did HCs [139].  These 
cells were found to degranulate after anti-CD3 stimulation, and importantly, a 
small number of these cells degranulated after stimulation with MBP and MOG 
peptides [139].  Increased levels of CX3CL1 were found in CSF derived from MS 
patients compared to HCs, and CD4+CD28- cells were found to preferentially 
migrate toward CX3CL1 in-vitro.  Lastly, CD4+CX3CR1+ T-cells were 
accumulated in active MS lesions, and the apoptotic maker cleaved caspase-3 
was expressed by oligodendrocytes in close proximity to CD4+CX3CR1+ T-cells, 
indicating that these cells may play a role in MS pathology by destroying myelin-
forming oligodendrocytes[139].   
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CX3CL1-CX3CR1 interactions mediate leukocyte-endothelial cell adhesion 
[145], have roles in both inflammation and neuroprotection [157], are found to be 
expressed in neurons, astrocytes, macrophages, and endothelia in MS lesions 
[169], are responsible for immune cell trafficking into the CNS in EAE [113], and 
correlate with the disease activity in MS patients [173]. Therefore, CX3CL1-
CX3CR1 interactions should be considered important to our understanding of MS 
pathology.  Our studies address roles for CX3CL1 in the induction of the 
adhesion molecule ICAM-1 expression and of proinflammatory cytokines such as 
IFN-γ, TNF-α, and IL-17A secretion, and migration of CD4+ T-cells. 
 
1.4 ICAM-1 is an Adhesion Molecule Critical for Transmigration through 
BBB  
Adhesion molecules coordinate with chemokines to direct lymphocytes 
towards the sites of inflammation [174, 175].  Adhesion molecules are critical for 
lymphocyte adhesion to BBB endothelia, and transmigration of lymphocytes into 
the CNS during EAE [106, 111].  Expression of adhesion molecules on circulating 
lymphocytes has been correlated with T2 lesion load [176], suggesting that 
elevated expression of adhesion molecules may affect CNS tissue damage in 
MS.   
ICAM-1 is a transmembrane adhesion molecule that is expressed on 
endothelia and leukocytes [177, 178].  ICAM-1 expression is regulated by several 
cytokines. IFN-γ, IL-1, IL-4, IL-6, IFN-γ, and TNF-α, lymphotoxin and 
lipopolysaccharide (LPS) stimulate its expression [177, 179], while TGF-β and IL-
10 inhibit its surface expression in several cell subsets [180].  CX3CL1 has been 
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shown to stimulate ICAM-1 surface expression in vascular endothelia [164]; 
however, its role in the regulation of ICAM-1 expression in leukocytes has not 
been studied. In this study, we will address a role for CX3CL1 in ICAM-1 
induction. 
Under inflammatory conditions, expression of ICAM-1 is increased on BBB 
endothelial cells (ECs) and is associated with the disruption of tight junctions, 
increased EC permeability, and increased migration of T-lymphocytes across the 
BBB [181, 182].  Data from EAE, pathological examination of MS CNS tissue, 
and in-vitro transendothelial migration assays suggest that the expression of 
ICAM-1 on endothelial cells may contribute to the pathogenesis of MS by 
controlling inflammatory cell migration across the BBB via interaction with 
leukocyte-expressed lymphocyte function-associated protein 1 (LFA-1) [112, 183-
186]. In EAE, BBB endothelial ICAM-1 expression is increased during relapses 
and decreased during remission, consistent with the hypothesis that ICAM-1 
surface expression on BBB endothelia is critical for EAE lesion formation [187].  
CD4+ T-lymphocyte expression of ICAM-1 is also required for the development of 
EAE [111].  Interestingly, roles for T-lymphocytes’ ICAM-1 expression in MS is 
less well understood than the one of endothelial ICAM-1. CX3CL1 has been 
shown to stimulate ICAM-1 surface expression in vascular endothelia; however, 
its role in the regulation of leukocyte ICAM-1 expression has not been studied 
[164]. 
A recent study has highlighted the requirement of ICAM-1 expression on 
T-cells for the development of EAE [111].  ICAM-1 null mice, induced with EAE, 
had attenuated clinical symptoms accompanied by a reduction of CD4+ and CD8+ 
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T-cell infiltration into the CNS, decreased axonal degeneration, and 
demyelination throughout the spinal cord [111].  Furthermore, transfer of ICAM-1 
null MOG-sensitized T-cells into the wild type (WT) mice failed to induce EAE or 
facilitate the transmigration of T-cells into the CNS, suggesting that ICAM-1 
expression on T-cells is required for EAE CNS lesion development [111].  Finally, 
ICAM-1 expression on T-cells, but not APCs, was found to be critical for T-cell 
proliferation [111].  The absence of ICAM-1 also reduced splenic T-cell 
production of IFN-γ, TNF-α, IL-4, IL-10 and IL-12 following MOG restimulation, 
and reduced CSF-derived CD4+ and CD8+ T-cell production of IFN-γ [111]. 
 
sICAM-1 
sICAM-1 lacks the transmembrane and cytoplasmic regions of ICAM-1 
and is produced by many cell types, including endothelia and leukocytes.  
Astrocyte- and endothelia-derived ADAM-17 cleave ICAM-1 to produce sICAM-1 
[152, 153].  sICAM-1 binds competitively to ICAM-1 ligands including LFA-1, and 
therefore has a therapeutic potential in MS.  sICAM-1 may therefore play a role in 
reducing T-cell transmigration via competitive inhibition of LFA-1-surface ICAM-1 
interactions [188, 189].  Indeed, serum levels of sICAM-1 have been shown to be 
increased in response to rIFNβ-1 treatment, and this increase is correlated with 
decreased contrast-enhancing brain MS lesion load [190].  Interestingly, in-vitro 
application of sICAM-1 to activated lymphocytes blocks their adhesion to CNS-
derived endothelial cells, and this effect is abrogated in a dose-dependent 
manner upon application of anti-ICAM antibody [189].  These data imply that 
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sICAM-1 may inhibit neurological damage in RRMS by blocking lymphocyte BBB 
transmigration via interference with adhesion molecule-mediated cell adhesion. 
Data pertaining to roles for sICAM-1 in MS are mixed, but sICAM-1 may 
act by competitively binding LFA-1 to block LFA-1-ICAM-1 interactions, and 
therefore transmigration across the BBB, in MS.  sICAM-1 has been shown to 
interfere with the adhesion of PBMCs to cerebral endothelial cells in-vitro, 
suggesting that it competes with ICAM-1 for interaction with LFA-1 [189].  
Furthermore, sICAM-1 serum levels in MS patients have been shown to be 
increased by treatment with rIFNβ-1b, paralleling a period of improvement as 
measured by decreased frequency of relapses, disability levels, and gadolinium-
enhancing lesion load [190]. In this context, suppressed CSF sICAM-1 
expression in MS patients in our study may be interpreted as an indicator of an 
inflammatory response, therefore enabling greater migration of inflammatory 
leukocytes across the BBB. 
 
1.5 Proinflammatory Cytokines IFN-γ and TNF-α are Potential 
Therapeutic Targets in MS 
Cytokines are critically involved in immune responses, and can be divided 
into proinflammatory cytokines and antiinflammatory cytokines.  Many of the 
proinflammatory cytokines are thought to play roles in MS pathogenesis, 
including in peripheral activation of circulating immune cells, as well as direct 
damage to myelin. Proinflammatory cytokines include IFN-γ, TNF-α, IL-17A, IL-
17F, IL-12, and IL-23.  Antiinflammatory cytokines are generally thought to play 
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disease-attenuating roles in MS, and include IL-4, IL-10, and TGF-β.  Here we 
will focus on the proinflammatory cytokines IFN-γ and TNF-α. 
Administration of IFN-γ, once proposed as a potential MS therapeutic, is 
now known to cause exacerbations in MS patients [110], perhaps due to its roles 
in the generation of cytotoxic T-cells and prevention of remyelination [191, 192].  
TNF-α is also known to play role in MS pathology.  TNF-α expression is 
increased in the CSF and MS lesions [193, 194], and is critical for the initiation of 
tissue damage in EAE [195, 196].  These effects are blocked by anti-TNF-α 
antibodies [197].  However, TNF-α has also been shown to have 
immunosuppressive effects at later EAE time points [198].  IFN-γ and TNF-α 
have been shown to stimulate CX3CL1 expression and release by endothelial 
cells, and CX3CL1 expression is increased in the IFN-γ-mediated Th1 disease 
psoriasis [199].  Immobilized CX3CL1 and CX3CL1-transfected 293E cells induce 
IFN-γ expression in NK-cells [200]. These data suggest that CX3CL1, IFN-γ, and 
TNF-α may act in an inflammatory positive feedback loop during Th1-mediated 
diseases. 
Results from studies regarding involvement of IFN-γ and TNF-α in MS 
pathology have been mixed; while several studies have shown IFN-γ mRNA 
levels to be increased in PBMCs derived from MS patients, and IFN-γ protein 
levels in serum derived from MS patients is enriched, several other studies report 
no differential IFN-γ expression between patients and controls [201, 202].  TNF-α 
has also been studied with conflicting results.  TNF- αhas been shown to induce 
oligodendrocyte cell death [203].  Several groups have found PBMC TNF-α 
mRNA levels, serum TNF-α, and secretion of TNF-α by PBMCs to be increased 
in MS patients [201, 204, 205].  Unfortunately, though, TNF-α-blocking therapies 
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such as sTNF-α receptor Ig fusion protein or anti-TNF-α mAb were found to 
worsen MS exacerbations [206]. 
Chemokine receptors that we analyzed on leukocyte subsets 
In recent years, several chemokine receptors and adhesion molecules 
such as CCR1, CCR4, CCR6, ICAM-1, and VLA-4 have been shown to play a 
role in the development of EAE, and blockade of these adhesion molecules and 
chemokine receptors via humanized monoclonal antibodies has led to the 
development of therapies that may decrease disease progression [111, 136, 138, 
207-209].  Here is a brief synopsis of what is known about each chemokine 
receptor and its relation to RRMS: 
CCR1. CCR1-/- mice exhibit reduced EAE symptoms, suggesting 
that CCR1 is critical for the development of neuroinflammation [209].  In humans, 
CCR1 is expressed on blood-derived T-cells and monocytes, and on CSF- and 
lesion-derived monocytes [46, 140, 210].  Its ligands are chemokines MIP-1α 
(CCL3), RANTES (CCL5), and MCP-3 (CCL7), CCL14 (HCC-1), CCL16 (HCC-4), 
and CCL23 (MPIF-1, CKβ8) (Table 1.2).  One study found that CCR1+ phagocytic 
cells accumulated in the perivascular areas of MS lesions [46], and that the 
CCR1 ligand CCL5’s concentration is elevated in CSF derived from RRMS 
patients [98].  Several groups have begun clinical trials using CCR1 small 
molecule antagonists as a treatment of RRMS and other inflammatory CNS 
disorders [211-213], but the data so far have been disappointing.  Oral CCR1 
antagonist BX471 was tested in clinical trials, with the primary endpoint of a 
number and volume of active Gd enhancing lesions on T1-weighted scans at 16 
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weeks after treatment onset in 105 MS patients [214].  No decrease in lesion 
formation was observed [214]. 
CCR2. CCR2 is expressed on monocytes, T-cells, B-cells, and DCs 
[215].  Its ligands include MCP-1 (CCL2), MCP-3 (CCL7), MCP-2 (CCL8), and 
HCC-4 (CCL16) [216] (Table 1.2).  Studies in EAE implicated that CCR2 plays a 
role in EAE induction and lesion formation [217].  CCR2 expression is increased 
in  RRMS lesion-derived  macrophages [142, 218], but T-cells and monocytes 
from RRMS patients have not shown differential expression of CCR2 compared 
to controls [219].  Migration of B-cells across the brain endothelial cells is 
dependent upon CCL2 [70]. 
CCR3. CCR3 is expressed on T-cells, B-cells, monocytes, 
eosinophils, and basophils.  CCR3 is a promiscuous chemokine receptor, which 
binds to RANTES (CCL5), MCP-3 (CCL7), MCP-2 (CCL8), Eotaxin-1 (CCL11), 
MCP-4 (CCL13), HCC-2 (CCL15), Eotaxin-2 (CCL24), Eotaxin-3 (CCL26), and 
MEC (CCL28) (Table 1.2).  CCR3 is expressed on macrophages in MS lesions, 
but has not been extensively studied in MS [218]. 
CCR5. CCR5 is expressed on multiple cell subsets, including T-
cells, B-cells, and monocytes.  Its ligands include MIP-1α (CCL3), LD78β 
(CCL3L1), RANTES (CCL5), and CCL14 (HCC-1) (Table 1.2).  Multiple lines of 
evidence point to the CCR5 involvement in the development of the inflammatory 
response in MS.  First, genetic evidence points to a pathological effect for CCR5.  
A cohort of individuals expresses the ―Δ32‖ CCR5 gene mutation, leading to the 
loss of functional expression of CCR5.  Interestingly, while Δ32 CCR5 
homozygotes are not protected from MS [220], Δ32 CCR5 heterozygotes with 
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RRMS experience significantly longer periods of remission than patients 
expressing functional CCR5 [221].  Second, several groups have shown 
increased CCR5 expression on blood-derived T-cells [98, 222], particularly during 
relapse [210], and CCR5+ T-cells were found to express higher levels of IFN-γ 
and TNF-α[223].  Last, CCR5+CD4+ T-cells and CCR5+CD8+ T-cells are also 
enriched in MS CSF compared to matched blood-derived cells, and cells derived 
from non-inflammatory neurological diseases (NINDs) controls and HCs.  CCR5 
is also expressed on macrophages and microglia [98].  Lastly, CCR5 is 
expressed on microglia and CD4+ T-cells in MS lesion tissue [218]. 
CCR6. CCR6 is expressed on T-cells, B-cells, and monocytes, and 
is the only receptor for CCL20 [224] (Table 1.2). With the recent discovery that 
CCR6 is a lineage marker for the TH17 CD4
+ T-cell subset, CCR6 expression has 
become an attractive focus of research in EAE and MS for their potential roles in 
pathology, as well as the search for Th17-targeting therapeutics [135].  CCR6 is 
expressed at similar levels on T-cells derived from blood and CSF of MS patients, 
and is expressed at similar levels during inflammation and in non-inflammatory 
controls [140].  In our study we did not find CCL20 to be differentially expressed 
in the CSF derived from RRMS patients and HCs 
CX3CR1. CX3CR1 is the lone receptor that interacts with the 
chemokine CX3CR1 (Table 1.2).  Because we found increased CX3CL1 
concentrations in the CSF from untreated RRMS patients in comparison to HCs, 
we chose to evaluate the differential expression of CX3CR1 on MS-related 
immune cell subsets derived from untreated RRMS patients compared to HCs. 
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Adhesion molecules that we analyzed on leukocyte subsets 
Adhesion molecules are involved in the inflammatory cell migration across 
the endothelial barriers, and the blockade of interaction between adhesion 
molecules and their ligands have been used as a treatment approach in MS.  
Particularly, blockade of VLA-4 interaction with VCAM-1—involved in BBB 
transmigration by several leukocyte subsets—by the humanized anti-VLA-4 
monoclonal antibody natalizumab, has demonstrated clinical efficacy in reducing 
the number of exacerbations and decreasing CNS lesion load in RRMS patients 
[208, 225].  Because of the importance of adhesion molecules in MS 
pathogenesis, we measured the expression of three adhesion molecules, ICAM-
1, VLA-4 and LFA-1 on CD4+ T-cells, CD8+ T-cells, CD19+ B-cells, and CD14+ 
monocytes in RRMS patients and HCs to address changes in adhesion molecule 
expression that may occur during MS and reflect changes in chemokines, 
cytokines, and chemokine receptor expression.  Following is a brief synopsis of 
what is known about each adhesion molecule and its relation to RRMS: 
VLA-4. VLA-4 is a ligand for VCAM-1, and its blockade via the 
monoclonal antibody natalizumab has proven to be an effective MS therapy due 
to attenuation of inflammatory cells migration through BBB [208, 225].  Because 
VLA-4 is proven to be critical for BBB transmigration and lesion formation, we 
decided to measure its expression levels on T-cells, B-cells, and monocytes. 
ICAM-1. ICAM-1 (a ligand for LFA-1) has been implicated in EAE and 
MS pathology, and became a major focus of our research when we found sICAM-
1 decreased levels in the CSF of untreated RRMS patients in comparison to HCs.  
We also noted that ICAM-1 expression on CD4+ and CD8+ T-cells is critical for 
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EAE induction [111], and that increased levels of CX3CL1 upregulate ICAM-1 via 
CX3CR1 [164].   We therefore hypothesized that in MS patients, in the presence 
of increased levels of CX3CL1, ICAM-1 would have increased expression on 
immune cell subsets in comparison to HCs. 
LFA-1. LFA-1 is an integrin that binds in trans with endothelial-
expressed ICAM-1 to allow migration of lymphocytes into the CNS for normal 
immunosurveillence and during neuroinflammation [225].  LFA-1 has recently 
been shown to require one of several bound chemokine receptors (CXCR4, 
CCR7, or CXCR3) so that it may bind ICAM-1 under shear stress conditions 
[175]. We hypothesized that LFA-1 may be expressed at increased levels on T-
cells, B-cells, or monocytes derived from untreated RRMS patients when 
compared to HCs. 
 
1.6 Rationale 
Initially, we focused on the expression of CX3CL1 in the CSF of MS 
patients. Using an inflammatory protein array approach, CX3CL1 was the only 
chemokine with increased expression in the CSF of MS patients in comparison to 
HCs. These results were confirmed and quantified by ELISA.  An increase in 
CX3CL1 concentrations has been shown to correlate with increased expression 
of CX3CR1 on circulating lymphocytes and monocytes during inflammatory 
disorders [226, 227].  Therefore, we asked, to what extent do increased CSF 
concentrations of CX3CL1 induce increased levels of CX3CR1 expression on 
lymphocytes and monocytes? We found that blood-derived CD4+ T-cells 
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selectively express increased surface levels of CX3CR1 in RRMS patients in 
comparison to HCs. 
Chemokines and chemokine receptors play a role in the regulation of 
surface expression of adhesion molecules in the inflammatory cells.  Therefore, 
we reasoned that since CX3CL1 levels are increased in MS CSF, and since 
CX3CR1 is up-regulated on CD4+ T-cells derived from MS blood, then the 
expression of adhesion molecules on CD4+ T-cells may be increased. We found 
that ICAM-1 surface expression is increased on CD4+ T-cells derived from MS 
patients in comparison to HCs, suggesting that CX3CL1-CX3CR1 signaling may 
lead to increased ICAM-1 expression on CD4+ T-cells. 
Next, we asked to what extent CX3CL1 increases gene expression and 
protein secretion of proinflammatory cytokines. We found that IFN-γ and TNF-α 
levels were significantly increased in CD4+ T-cells derived from RRMS patients 
cultured in the presence of CX3CL1.  However, this increase was not observed in 
CD4+ T-cells derived from HCs.  We also found that IL-17A gene expression was 
increased in CD4+ T-cells incubated in the presence of CX3CL1 when derived 
from RRMS patients compared to HCs.  However, the increase was not 
statistically significant.  To address whether increases in IFN-γ gene expression 
resulted in greater protein secretion of IFN-γ, we incubated CD4+ T-cells in the 
absence or presence of CX3CL1.  CD4+ T-cells derived from RRMS patients but 
not those derived from HCs secreted higher levels of IFN-γ compared to control 
cell cultures.  However, we found no changes in the secretion of IL-4, TNF-α, IL-
17A, or IL-17F.  
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Lymphocyte extravasation from the bloodstream into the CNS is a critical 
component of RRMS pathogenesis.  The molecular profile of lymphocytes found 
in the CSF of MS patients has been shown to mirror the molecular profile of 
lymphocytes which populate MS lesions [98].  Therefore, we reasoned that if 
CX3CR1 and ICAM-1 upregulation on CD4+ T-cells is critical during cell 
transmigration across the BBB, then CSF-derived CD4+ T-cells will express 
higher surface levels of CX3CR1 and ICAM-1 than matched blood-derived CD4+ 
T-cells. We found that CD4+ T-cells derived from the CSF of MS patients express 
significantly higher levels of CX3CR1 and ICAM-1 than the matched blood-
derived CD4+ T-cells. 
To further investigate the functional role of CX3CL1 in CD4+ T-cell 
migration, we performed CD4+ T-cell migration in-vitro assays directed toward 
CX3CL1, and found that CD4+ T-cells preferentially migrate toward CX3CL1 in a 
concentration-dependent manner, with 1 ng/mL concentration inducing a maximal 
migration.  We then examined if CD4+ T-cells that migrated toward CX3CL1 
gradient express higher levels of CX3CR1 and ICAM-1 than CD4+ T-cells which 
do not migrate toward CX3CL1. We found that CX3CR1 and ICAM-1 expression 
were higher on cells that migrated toward CX3CL1 compared to those which did 
not migrate against this chemokine gradient. 
These results suggested that CX3CL1-CX3CR1 interactions might play a 
role in the increased expression of ICAM-1 on CD4+ T-cells.  To determine if 
increased CX3CL1 levels led to the upregulation of ICAM-1, we incubated 
PBMCs in the presence of CX3CL1, and found that the percentage of ICAM-1+ 
CD4+ cells increased in MS patients but not in HCs. 
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In order to address the above findings in the context of myelin-specific 
immune response, relevant for this demyelinating disease, we co-incubated 
myelin-antigen specific CD4+ T-cell lines with APCs in the presence or absence 
of native myelin peptide and CX3CL1.  We found that ICAM-1 was selectively 
increased in the presence of both CX3CL1 and myelin peptide in myelin-reactive 
CD4+ T-cell lines.  This indicated that CX3CL1 in the presence of antigen 
increased ICAM-1 expression on the surface of activated myelin-reactive CD4+T-
cells to a greater degree than antigen or CX3CL1 alone.  Taken together, these 
data indicate that CX3CL1, CX3CR1, ICAM-1, IFN-γ and TNF-α interact to play 
previously undefined roles in the development of the inflammatory response in 
MS. 
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Figure 1.1 MS Pathogenesis 
 
Figure 1.1 Four steps of MS immunopathogenesis: 
A. Myelin-autoreactive CD4+Th cells are activated in peripheral circulation 
B. Activated CD4+T-cells migrate through permeable BBB  
C. CD4+T-cells encounter APCs (i.e. microglia and DCs), and are reactivated by 
myelin-derived antigens. Cytokine production increases, influx of inflammatory 
cells. 
D. Myelin destruction and axonal transection 
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Table 1.1. Cytokines and other proteins that interact with CX3CL1 and CX3CR1 
Proteins Cell subset Interaction Function Ref. 
IL-1/TNF-α 
HPAEC/ 
HUVEC 
IL-1 and TNF-α increase expression of 
fractalkine mRNA 
Fractalkine induction by 
proinflammatory cytokines 
[143] 
IL-2/NFAT2 PBMCs(h) 
IL-2 upregulates CX3CR1 via recruitment 
of NFAT2 to CX3CR1 promoter 
CX3CR1 induction by 
proinflammatory cytokines 
[158] 
sIL-6Rα HUVEC 
sIL-6R inhibits IL-1 or IFN-γ-induced 
expression of CX3CR1 via signaling 
through gp130. 
Decreases adhesion of 
mononuclear cells to 
endothelia 
[162] 
IL-10 Monocytes (h) 
IL-10 increases surface expression of 
CX3CR1 via PI3K 
Increased surface 
expression of CD11b, 
indicating monocyte 
activation 
[160] 
CXCL8/IL-12/ 
IL-15 
CD16
-
 NK cells 
Incubation with CXCL8, IL-12, and IL-15 
decrease expression of CX3CR1 
Production of fractalkine 
[228] 
IL-15 / NFAT1 PBMCs(h) 
IL-15 downregulates CX3CR1 
expression via recruitment of NFAT1 to 
CX3CR1 promoter 
Regulation of CX3CR1 
expression by cytokines 
[158] 
IFN-γ Monocytes (h) 
IFN-γ increases surface expression of 
CX3CR1 via PI3K. 
Regulation of CX3CR1 
expression by cytokines 
[160] 
IFN-γ HUVEC IFN-γ increases expression of CX3CR1. 
Increases adhesion of 
PBMCs to HUVECs  
[161] 
CCL2 Monocytes (h) 
CCL2-CCR2 interactions stimulate 
surface expression of CX3CR1 
expression via p38 MAPK 
Increases adhesion of 
monocytes to fractalkine 
[159] 
IL-6/CCL2/ 
MMP-9 
Monocytes 
CD16
+
 monocytes produce IL-6, CCL2, 
and MMP-9 after interacting with 
fractalkine-expressing HUVECs 
The supernatants from this 
culture induce neuronal cell 
death in-vitro 
[156] 
IL-6/NO/ 
TNF-α 
Murine 
microglia 
Fractalkine suppressed production of IL-
6, NO, and TNF-α  
Fractalkine suppressed 
neuronal cell death induced 
by activated microglia 
[157] 
ICAM-1 
HPAEC 
/HUVEC 
Fractalkine-CX3CR1 binding upregulates 
ICAM-1 expression via JAK2-STAT5 
pathway 
Promotion of neutrophils 
adhesion  
[164] 
Akt/PI3K/ 
NF-κB 
Hippocampal 
neurons (r) 
Upon exposure to fractalkine, CX3CR1-
expressing hippocampal neurons 
upregulate the expression of pro-survival 
proteins 
neuroprotection 
[165] 
CCL26 
L1.2 cells, 
HUVECs 
CCL26 binds to CX3CR1 
CCL26 induces Ca
++ 
mobilization, chemotaxis, 
and adhesion to L1.2 cells 
[229] 
RANKL/PI3K/ 
Akt 
RAW264.7 
(macrophage 
cell line, m) 
RANKL induces downregulation of 
CX3CR1 mRNA via PI3K/Akt pathway. 
Inhibition of chemotaxis 
[163] 
ADAM10 
ECV-304 
(urinary bladder 
carcinoma, h), 
fibroblasts (m) 
ADAM10 is required for the constitutive 
cleavage of fractalkine from the cell 
surface, producing fractalkine 
Production of fractalkine 
[230] 
ADAM17 
ECV-304, 
CHO, HUVEC 
ADAM17 is responsible for the inducible 
cleavage of fractalkine 
Production of fractalkine 
[147, 
149] 
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Table 1.2. Chemokines and chemokine receptors 
Receptor 
Chemokin
e 
Old nomenclature 
 
Receptor Chemokine 
Old 
nomenclature 
CC family 
 
CXC family 
CCR1 CCL3 MIP-1α 
 CXCR1 
CXCL1 GRO-α 
  CCL3L1 LD78β 
 
CXCL6 GCP-2 
  CCL5 RANTES 
 
CXCL8 IL-8 
  CCL7 MCP-3 
 
CXCR2 
CXCL1 GRO-α 
  CCL14 HCC-1 
 
CXCL2 GRO-β 
  CCL15 
HCC-2, Lkn-1, MIP-
1α 
 
CXCL3 GRO-γ 
  CCL16 HCC-4 
 
CXCL5 ENA-78 
  CCL23 MPIF-1, CKβ8 
 
CXCL6 GCP-2 
CCR2 CCL2 MCP-1 
 
CXCL7 NAP-2 
  CCL7 MCP-3 
 
CXCL8 IL-8 
  CCL8 MCP-2 
 
CXCR3 
CXCL4 PF4 
  CCL13 MCP-4 
 
CXCL9 Mig 
CCR3 CCL5 RANTES 
 
CXCL10 IP-10 
  CCL7 MCP-3 
 
CXCL11 I-TAC 
  CCL8 MCP-2 
 
CXCR4 CXCL12 SDF-1 
  CCL11 Eotaxin-1 
 
CXCR5 CXCL13 BLC/BCA-1 
  CCL13 MCP-4 
 
CXCR6 CXCL16   
  CCL15 
HCC-2, Lkn-1, MIP-
1Δ 
 
Unknown CXCL14 BRAK 
  CCL24 Eotaxin-2, MPIF-2 
 
  
 CX3C 
family 
  
  CCL28 MEC 
 
CX3CR1 CX3CL1 Fractalkine 
CCR4 CCL17 TARC 
 
C family 
  CCL22 MDC, STCP-1 
 
XCR1 XCL1 Lymphotactin 
CCR5 CCL3 MIP-1α 
 
XCR2 XCL2 SCM-1β 
  CCL3L1 LD78β 
    CCL4 MIP-1β 
 
Adapted from [231]. 
    CCL5 RANTES 
      CCL14 HCC-1 
    CCR6 CCL20 MIP-3α, exodus-1 
    CCR7 CCL19 MIP-3β, exodus-3 
      CCL21 SLC, exodus-2 
    CCR8 CCL1 I-309 
    CCR9 CCL25 TECK 
    
CCR10 
CCL27 CTACK, ILC 
    CCL28 MEC 
    
Unknown CCL18 
PARC, DC-CK1, 
AMAC1 
 
   
  
CHAPTER 2 
CX3CL1 increases Intercellular Adhesion Molecule-1 on CD4+ T 
Lymphocytes: Implications for the Immunopathogenesis of MS 
 
2.1 INTRODUCTION 
MS is an inflammatory, demyelinating CNS disease that is characterized 
by chemokine- and adhesion molecule-dependent infiltration of the CNS by 
activated, self-reactive CD4+ T-cells [1, 39, 139].   Membrane-bound CX3CL1 
functions as an adhesion molecule, and is expressed on CNS neurons and 
endothelium [144].  It is comprised of an N-terminal chemokine domain, attached 
to a mucin-like stalk, followed by transmembrane and intercellular domains [143].  
Inflammation and neuronal damage cause the chemokine domain to be cleaved 
by the metalloproteinase ADAM-17 [149, 232], which may contribute to increased 
CSF and serum levels of CX3CL1 in MS and other inflammatory diseases [226, 
227, 233].  Proinflammatory cytokines IFN-γ and TNF-α induce CX3CL1 
expression and release by endothelium, while anti-inflammatory cytokines IL-4 
and IL-13 inhibit CX3CL1 expression [199]. CX3CL1 expression is increased in 
the IFN-γ-mediated Th1 disease psoriasis, but not in Th2-dominated atopic 
dermatitis [199]. Immobilized CX3CL1 and CX3CL1-transfected 293E cells 
increase the IFN-γ expression in NK-cells [200].  Together, these data suggest 
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that CX3CL1 and IFN-γ may act in an inflammatory positive feedback loop during 
Th1-mediated diseases [199, 200]. CX3CR1 is a G-protein coupled receptor 
expressed by microglia, monocytes, NK-cells and T-cells [145, 170].  
CX3CR1+CD4+ T-cells are present in lesions derived from RRMS patients [139], 
indicating that CX3CL1 may recruit CX3CR1+CD4+ T-cells into CNS 
demyelinating lesions 
CX3CL1 stimulates ICAM-1 surface expression in vascular endothelia 
[164]; however, its role in the regulation of ICAM-1 expression in leukocytes is 
unknown.  ICAM-1 is an Ig-like, transmembrane cell adhesion molecule 
expressed on vascular endothelial cells, T-cells, B-cells and monocytes [177, 
178].  CD4+ T-cell expression of ICAM-1 is critical for the induction of the MS 
disease model EAE [111].  ICAM-1 is regulated by several cytokines: IFN-γ, TNF-
α, IL-1, IL-4, IL-6, lymphotoxin and LPS stimulate its expression [177, 179], while 
TGF-β and IL-10 inhibit it in several cell subsets [180].  Similar to membrane-
bound CX3CL1, ICAM-1 is cleaved by ADAM-17 during inflammation to produce 
sICAM-1 [153].  sICAM-1 binds competitively to the ICAM-1 ligand LFA-1, whose 
expression on lymphocytes is critical for their transmigration across the BBB 
[178].  Serum levels of sICAM-1 are increased during rIFNβ-1b treatment, and 
this increase correlates with a decrease in contrast-enhancing MS brain lesion 
load [190].  Therefore, circulating sICAM-1 may play a role in reducing T-cell BBB 
transmigration via competitive inhibition of LFA-1-ICAM-1 interactions [189]. 
We hypothesized that increased CX3CL1-CX3CR1 interactions induce 
ICAM-1 and IFN-γ expression in CD4+ T-cells, and that CX3CR1+ICAM-1+CD4+ 
T-cells are enriched in the CSF during RRMS. The present study has identified 
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an increase in CX3CL1, and a decrease in sICAM-1 in the CSF of RRMS patients 
in comparison to HCs, and has shown an increase in the percentage of 
CX3CR1+ICAM-1+CD4+ T-cells derived from CSF compared to blood of early 
untreated RRMS patients.  CX3CL1 induced an increased IFN-γ gene expression 
and protein secretion in RRMS-derived but not in HC-derived CD4+ T-cells.  
CX3CL1 was also found to increase ICAM-1 expression on the surface of RRMS-
patient-derived but not HC-derived CD4+ T-cells, and on stimulated myelin-
antigen-specific CD4+ T-cell lines.  These results indicate that CX3CL1 may play 
a pathological role in RRMS by enhancing migration of IFN-γ-secreting 
CX3CR1+ICAM-1+CD4+ T-cells into the CNS. 
 
2.2 MATERIALS AND METHODS 
2.2.1  Study Subjects 
48 RRMS patients (average age = 44 yrs. 5 mos., sex = 34 F / 14 M, race 
= 35 Caucasian, 13 African American, disease duration 3 yrs. 11 mo. and 38 HC 
patients (average age = 43 yrs. 4 mos., sex = 25 F / 13 M, race = 31 Caucausian, 
7 African American) were enrolled in this study after signing an institutional 
review board-approved consent form.  None of the RRMS patients had received 
immunomodulatory or immunosuppressive treatments prior to the CSF or blood 
sample collection. 
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2.2.2  CSF samples 
CSF samples were collected for the purposes of diagnosis and/or this 
study.  CSF sample was centrifuged for 6 minutes; supernatant was removed and 
stored at -80°C until protein measurements.   
 
2.2.3 CD4+ T-lymphocyte isolation 
PBMCs were obtained from blood samples by Ficoll-Paque gradient 
centrifugation.  Further isolation of CD4+ T-lymphocytes was performed by 
magnetic bead separation (Miltenyi biotech, Auburn, CA).  The negatively-
selected CD4+ T-lymphocytes were > 95% pure as demonstrated by FACS 
analysis. 
 
2.2.4  Protein Array 
Cytokine array C Series 1000 (RayBiotech, Inc., Norcross, GA) was used 
as described previously [234].  Briefly, membranes were blocked for 30 min. in 
blocking buffer.  They were then incubated in 1 mL CSF at room temperature for 
two hours.  After incubation, membranes were washed and incubated with the 
appropriate Biotin-conjugated antibodies for two hours.  Wash steps were 
repeated, 1:1000-diluted HRP-conjugated streptavidin was applied for two hours 
followed by wash steps.  Detection buffers were applied for two minutes, and 
membranes were exposed to HyBlot CL autoradiography film (Metuchen, NJ) for 
1 – 30 s.  Membranes were then scanned with an Epson America Expression 
1680 Scanner (Epson America Inc., Long Beach, CA). Meta Imaging Series 5.0 
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software (Molecular Devices, Downington, PA) was used to quantify signal 
intensities as previously described [89]. The lowest value on the membrane was 
considered the background, and was subtracted from all measured proteins.  For 
the purpose of comparisons between membranes, results were normalized as 
follows: the background measurement was subtracted from all measured 
proteins.  The results were normalized by dividing each protein value by the sum 
of optical density values for all proteins on the membrane.  The relative protein 
level results were expressed in arbitrary units (AUs) of the untreated RRMS CSF 
in comparison to HC CSF.Proportion of total signal. 
1. corrected density = average of background - raw density 
2. normalized density = LOG (100 / (highest corrected density - corrected density) 
/ highest corrected density x 100) 
3. Relative protein expression in arbitrary units (AU) = average of normalized 
density of duplicates / sum of normalized density of all protein spots in single 
membrane 
 
2.2.5  ELISA 
CSF and CD4+ T-lymphocyte supernatants (SNs) were collected as 
described above, and ELISAs for CX3CL1, sICAM-1 (R&D), IFN-γ  (BD 
Biosciences), and fibroblast growth factor 6 (FGF-6) (RayBiotech, Inc.) were 
performed as per manufacturer’s instructions. 
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2.2.6  Chemotaxis Assays 
Separated CD4+ and CD8+ T-cells were independently assessed via flow 
cytometry to assure a purity of >95%.  A transwell system with pore size 5 μm 
(Neuroprobe, Gaithersburg, MD, USA) was utilized for the chemotaxis assay.  In 
the lower compartment, the CX3CL1 chemokine domain (R&D) was added to the 
media in increasing concentrations (0, 0.1, 1.0, 10.0 ng/ml).  Each upper 
chamber was seeded with 5X105 CD4+ T-cells, and incubated for four hours at 
37°C/5% CO2.  The total number of cells that migrated into the lower 
compartment was counted, and chemotactic index was determined as described 
[139]: (number of cells migrated toward CX3CL1 / number of cells migrated in the 
absence of CX3CL1) 
 For analysis of migrated cells by flow cytometry, a longer migration 
protocol was used to increase total numbers migrated.  In this assay, isolated 
CD4+ T-cells migrated toward the optimal concentration of CX3CL1 (1 ng/mL) for 
18 hours, and then were immediately immunostained and analyzed via flow 
cytometry. 
 
2.2.7  Flow cytometry 
Four-color flow cytometry acquisition was performed using BD 
FACScalibur hardware and CellQuest Pro software (both BD Biosciences, San 
Jose, CA). Cells were gated on lymphocyte or monocyte population and cell 
subset using the following antibodies: CD4 PE-Cy5, CD8 PE-Cy5 or CD8 FITC, 
CD19 PE-Cy5, and CD14 PerCP-Cy5.5 (BD Biosciences).  At least 40,000 blood-
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derived lymphocytes or monocytes and up to 10000 CSF-derived mononuclear 
cells were analyzed per experiment.    Chemokine receptors were analyzed by 
staining with the following antibodies: APC-CCR1 (R&D, Minneapolis, MN), APC-
CCR2, PE-CCR3, FITC-CCR5, FITC-CCR6 (all BD Biosciences), and PE-
CX3CR1  (US Biologicals, Swampscott, MA).  Adhesion molecules were 
analyzed using the following antibodies: APC-VLA-4 (R&D), FITC-LFA-1, PE-
ICAM-1, and APC-ICAM-1 (all BD Biosciences). 
 Where indicated, in vitro-expanded myelin peptide-specific CD4+ T-cell 
lines were co-cultured with EBV-immortalized B-cells and stimulated with 
antigenic peptide (10 μg/ml MBP83-99, PLP180-199, or control influenza virus 
hemagglutinin (FluHA)306-318 peptide) in the absence or presence of CX3CL1 (1 
ng/ml) for 48 h prior to ICAM-1 cell surface expression measurement using flow 
cytometry. 
 
2.2.8  Quantitative RT-PCR 
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA), and 
cDNA was synthesized using a High Capacity cDNA Archive Kit (Applied 
Biosystems, Branchburg, NJ).  The primers for IFN-γ, IL-17A and TNF-α were 
purchased from Applied Biosystems.  TaqMan Gene Expression Assay (Applied 
Biosystems) was used to measure gene expression via quantitative RT-PCR in 
duplicate.  All results are expressed as relative gene expression normalized 
against 18S mRNA expression. 
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2.2.9  Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software 
(Graphpad software, San Diego, CA).  Student’s t-tests were utilized to analyze 
comparisons between two groups.  Significance was achieved when p values 
were less than 0.05.  A repeated measures ANOVA was used for comparison 
analysis of multiple groups, followed by an appropriate posttests. 
 
2.3 RESULTS 
2.3.1  CX3CL1 Levels are Increased and sICAM are Decreased in CSF of 
RRMS Patients in Comparison to HCs 
An inflammatory protein profile of CSF derived from RRMS patients may 
provide clues that will lead to more accurate early diagnosis and treatments for 
RRMS. The protein array analysis that contained 120 cytokines, chemokines, 
neurotrophic factors, and adhesion molecules, was performed using the CSF of 
10 RRMS patients and 19 HCs.  
CX3CL1 was the only chemokine found to be increased in RRMS CSF vs. 
HC CSF (2.0-fold increase, p = 0.011) (Fig. 2.1A).  The complete set of array 
data are presented in Supplementary Fig. 1.  To confirm and quantify differences 
in CX3CL1 levels found in the cytokine array, CX3CL1 concentrations in the CSF 
from an independent cohort of 18 RRMS patients and 15 HCs were evaluated by 
ELISA.  This confirmed that CX3CL1 levels were higher in RRMS patients’ than 
HC CSF (Fig. 2.1B, 2.9-fold increase, p = 0.017). 
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sICAM-1 was found to be significantly decreased in the CSF derived from 
RRMS patients in comparison to HCs (Fig. 2.1C, 5.6 -fold decrease, p = 0.0046). 
sICAM-1 levels in the CSF were further quantified by ELISA.  sICAM-1 levels 
were confirmed to be lower in the CSF derived from 18 untreated RRMS patients 
in comparison to 15 HCs (Fig. 2.1D, 5.9-fold decrease, p = 0.0027). 
 
2.3.2  CX3CL1 Increases Gene Expression and Protein Secretion of 
Proinflammatory Cytokines in CD4+ T-cells Derived from RRMS Patients but 
not from HCs 
Because CX3CL1 has been shown to induce IFN-γ expression in NK-cells 
[200], we wondered if IFN-γ gene expression is also increased in CD4+ T-cells in 
the presence of CX3CL1. The levels of IFN-γ gene expression in CD4+ cells from 
7 RRMS patients and 6 HCs was analyzed after 6 h incubation in the absence or 
presence of CX3CL1.  IFN-γ gene expression was significantly increased in CD4+ 
T-cells derived from RRMS patients in comparison to HCs (Fig. 2.2A, 2.2-fold).  
CX3CL1 also induced higher gene expression of IFN-γ in CD4+ T-cells derived 
from RRMS patients compared to CD4+ T-cells derived from HCs(Fig. 2.2A, 4.7-
fold).No significant difference of IFN-γ gene expression was found between CD4+ 
T-cells from HCs, cultured in the absence or presence of CX3CL1 (Fig. 2.2A). 
CX3CL1 has been shown to induce TNF-α  during Th1-
mediated inflammation [199]. Therefore, we examined to what extent CX3CL1 
may upregulate TNF-α gene expression.  In CD4+ T-cells derived from 6 RRMS 
patients and 6 HCs, CX3CL1 significantly increased TNF-α gene expression in 
CD4+ T-cells from RRMS patients, but not from HCs (Fig. 2.2A, 2.1-fold).   CD4+ 
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T-cells from 6 RRMS patients  cultured with CX3CL1also showed higher IL-17A 
gene expression than CD4+ T-cells from 6 HCs, but this change did not reach 
significance (Fig. 2.2A, 2.7-fold). 
We asked whether the CX3CL1-induced increase in IFN-γ gene 
expression in RRMS patient-derived CD4+ T-cells led to an increased secretion of 
IFN-γ.  CD4+ T-cells derived from the blood of 6 RRMS patients and 6 HCS were 
incubated in 1 ng/ml CX3CL1 for 48 h, and supernatants were harvested to 
measure cytokine secretion using ELISA.  CX3CL1 increased IFN-γ secretion by 
CD4+ T-cells derived from RRMS patients but not from HCs (Fig. 2.2B, 12.5-fold).  
CX3CL1 also induced a significantly greater increase in IFN-γ secretion in RRMS 
CD4+ T-cells compared to HCs (Fig. 2.2B, 5.1-fold). 
 
2.3.3  CX3CR1+CD4+ T-cells are Enriched in Blood Samples Derived from 
Untreated RRMS Patients in Comparison to HCs 
Cell surface expression of chemokine receptors is determined in part by 
the extracellular molecular environment [199].  Thus, we proposed that the 
expression of CX3CR1 and other chemokine receptors may be increased on the 
cell surfaces of circulating mononuclear cells in MS.  To evaluate differences in 
chemokine receptor expression on T-cells, B-cells, and monocytes that may 
correspond to increased levels of CX3CL1 in RRMS-derived CSF, flow cytometry 
analysis of the aforementioned cell subsets was performed to identify the 
percentage of each cell subset that had a surface expression of CX3CR1.  Other 
chemokine receptors that have been implicated in neuroinflammation were also 
analyzed (CCR1 [235], CCR2 [218], CCR3 [222], CCR5 [218], CCR6 [135]).  
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Among the six chemokine receptors analyzed on CD4+ T-cells derived from 8 
RRMS patients and 10 HCs, CX3CR1 was the only chemokine receptor that was 
expressed on a significantly higher percentage of CD4+ T-cells from RRMS 
patients in comparison to HCs (Fig 2.3A, 3.3-fold, p = 0.034).   
The same panel of chemokine receptors was analyzed on CD8+ T-cells 
derived from 8 RRMS patients and 10 HCs.  The only chemokine receptor that 
was expressed on a significantly higher (percentage of CD8+ T-cells from RRMS 
patients was CCR5 (Fig 2.3B, 2.0-fold, (p = 0.043).  Expression of these 
chemokine receptors was also evaluated on CD19+ B-cells from 8 RRMS patients 
and 8 HCs.  We found that the percentage of CCR2+ B-cells derived from RRMS 
patients was significantly lower than in HCs (Fig 2.3C, 3.0-fold, p = 0.037).  No 
differences in chemokine receptor expression were observed on CD14+ 
monocytes derived from 7 RRMS patients and 7 HCs (Fig. 2.3D). 
 
2.3.4 The Percentages of ICAM-1+CD4+ and ICAM-1+CD8+T-cells are 
increased in Blood Samples Derived from RRMS Patients in comparison to 
HCs  
Chemokines signal through chemokine receptors and upregulate surface 
expression of adhesion molecules [164].  Thus, we measured surface expression 
of three adhesion molecules that may be regulated by the interaction of 
chemokines and corresponding receptors, which play a role in the development 
of the inflammatory response in MS—ICAM-1 [164], VLA-4 [236], and LFA-1 
[175]—on CD4+, CD8+ T-cells, CD19+ B-cells, and CD14+ monocytes.   The 
percentages of ICAM-1+CD4+ T-cells (Fig. 2.4A) and ICAM-1+CD8+ T-cells (Fig. 
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2.4B) were increased in blood samples derived from 8 RRMS patients when 
compared to 10 HCs.  The percentage of CD4+ T-cells expressing ICAM-1 was 
2.5-fold higher (p = 0.0004) on CD4+ T-cells from RRMS patients in comparison 
to HCs (Fig. 2.4A).  The percentage of ICAM-1+CD8+T-cells was 1.5-fold higher 
in RRMS patients in comparison to HCs (Fig 2.4B. p = 0.016).  No differences in 
adhesion molecule expression between RRMS patients and HCs were observed 
on CD19+ B-cells (8 RRMS patients, 8 HCs) (Fig. 2.4C) or CD14+ monocytes (7 
RRMS patients, 7 HCs) (Fig. 2.4D).   
 
2.3.5 The Percentages of CX3CR1+ICAM-1+CD4+ T-lymphocytes are 
significantly increased in RRMS-derived CSF Compared to the 
Corresponding Blood Samples 
In order to determine whether CD4+ and CD8+ T-cells that have migrated 
into the CSF during RRMS have elevated levels of surface CX3CR1 and ICAM-1, 
flow cytometry studies were performed on PBMCs and corresponding CSF-
derived mononuclear cells from 9 RRMS patients at the time of establishing 
diagnosis.   
The percentage of CX3CR1+CD4+ T-cells was increased in the CSF 
derived from 9 RRMS patients in comparison to the corresponding blood samples 
(Fig. 2.5A, 4.0-fold, p = 0.00028).  CX3CR1 surface expression was measured 
also via mean fluorescence intensity (MFI) readings, and found that CX3CR1 MFI 
was significantly higher on 7 CSF sample-derived CD4+ T-cells than on 7 blood 
sample-derived CD4+ T-cells (Fig. 2.5A., 4.2-fold, p = 0.00082). 
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The percentage of ICAM-1-positive CD4+ T-cells derived from CSF was 
also significantly higher than ICAM-1+CD4+ T-cells derived from corresponding 
blood samples (Fig. 2.5A, 1.5-fold, p = 0.013).  MFI of ICAM-1 expression on 
CD4+ T-cells was significantly higher in CSF-derived CD4+ T-cells compared to 
blood (Fig. 2.5A, 2.1-fold, p = 0.006) indicating that ICAM-1 is up-regulated on 
CD4+ T-cells that have migrated into the CSF during RRMS.  Finally, we 
analyzed percentages of CX3CR1+CD4+ T-cells derived from CSF vs. blood that 
co-express ICAM-1, and found that a significantly greater proportion of 
CX3CR1+CD4+ T-cells express ICAM-1 in CSF-derived cells than on blood-
derived CX3CR1+CD4+ T-cells (Fig. 2.5A, p = 0.013). 
CD8+ T-cells derived from the CSF of RRMS patients did not exhibit 
significantly higher percentages of CX3CR1 or ICAM-1 than blood-derived CD8+ 
T-cells (Fig. 2.5B).  However, CX3CR1 MFI (5.4-fold, p = 0.021) on CD8+T-cells 
was significantly higher on CSF-derived CD8+ T-cells (Fig. 2.5B).  CSF-derived 
CX3CR1+ICAM-1+CD8+ T-cells were also not found to be present in higher 
percentages in CSF compared to blood samples (Fig. 2.5B).  
 
2.3.6  CD4+ T-cells Migrate Toward CX3CL1 in a Dose-dependent Manner 
We next utilized an in-vitro migration assay to test the hypothesis that 
CD4+ T-cells migrate toward CX3CL1 gradient.  In chemotaxis assays involving 
CD4+ and CD8+ T-cells derived from RRMS patients, we found that CD4+ but not 
CD8+ T-cells migrated in a concentration-dependent manner toward CX3CL1 
gradient with 1 ng/ml concentration inducing maximal cell migration (Fig. 2.6A). 
55 
 
 Because CX3CR1+ICAM-1+CD4+ T-cells are enriched in RRMS CSF 
compared to corresponding blood samples, we hypothesized that 
CX3CR1+ICAM-1+CD4+ T-cells may preferentially migrate toward CX3CL1 in-
vitro.  CD4+ T-cells derived from 4 RRMS patients and 4 HCs were used in the 
migration experiments toward optimal CX3CL1 concentration (1 ng/ml) for 18 h.  
After migration, CX3CR1 and ICAM-1 surface expression was determined in 
migrated and non-migrated cells using flow cytometry.  A significantly higher 
percentage of migrated CD4+ T-cells derived from RRMS patients (Fig. 2.6B, p = 
0.01) and HCs (Fig. 2.6B, p = 0.01) expressed ICAM-1 than non-migrated CD4+ 
T-cells.  A significantly higher percentage of migrated CX3CR1+CD4+T-cells 
derived from RRMS patients (Fig. 2.6B, p = 0.03) and HCs (p =0.03) expressed 
ICAM-1 than did non-migrated cells.  In addition, a significantly higher percentage 
of migrated CD4+ T-cells derived from RRMS patients expressed ICAM-1 than 
migrated CD4+ T-cells from HCs (p = 0.0078).  Combined data from 4 RRMS and 
4 HC assays indicated that a higher percentage of migrated CD4+ T-cells 
expressed ICAM-1 than non-migrated CD4+ T-cells (p= 0.000019). 
 
2.3.7  CX3CL1 Induces the Surface Expression of ICAM-1 on CD4+ T-
lymphocytes Derived from Blood of RRMS Patients but not of HCs 
High concentrations of CX3CL1 in the CSF and blood may be responsible 
for the increase in the percentage of CX3CR1+ and ICAM-1+ CD4+ T-cells found 
in RRMS.  To test if CX3CL1 up-regulates CX3CR1 and ICAM-1 in-vitro, we 
incubated freshly isolated PBMCs from 7 RRMS patients and 7 HCs in the 
absence or presence of 1 ng/ml CX3CL1.  A significantly higher percentage of 
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CD4+ T-cells derived from RRMS patients incubated with 1 ng/ml CX3CL1 
expressed ICAM-1 than in chemokine-free cultures, (Fig. 2.7, 1.8-fold).  CX3CL1 
did not induce up-regulation of ICAM-1 in CD4+ T-cells derived from HCs (Fig. 
2.7).  CD4+ T-cells derived from RRMS patients cultured in the presence of 
CX3CL1 expressed significantly higher levels of ICAM-1 than CD4+ T-cells 
derived from HCs. (Fig. 2.7, 2.5-fold).  CX3CL1 was not found to induce CX3CR1 
expression on CD4+ T-cells from RRMS patients and HCs. 
 
2.3.8  CX3CL1 Induces Expression of ICAM-1 on myelin-Ag-specific CD4+ T-
cells 
Myelin-autoreactive CD4+ T-cells play a role in the initiation and 
perpetuation of the inflammatory response in MS [3, 37].  To explore whether 
myelin-reactive CD4+ T-cells increase the expression of chemokine receptors and 
adhesion molecules in response to myelin peptide stimulation and CX3CL1, 3 
myelin-Ag specific CD4+ T-cell lines (1 PLP180-199-specific, 2 MBP83-99-specific 
lines) were activated in the absence or presence of CX3CL1, along with native 
antigenic peptide for 48 h, and surface chemokine receptors and adhesion 
molecules expression was measured by flow cytometry (Fig. 2.8A).In each myelin 
Ag-specific line, ICAM-1 expression as measured by MFI was found to be higher 
in Ag- and CX3CL1-stimulated CD4+ lymphocytes than in baseline conditions 
(Fig. 2.8A. representative histogram Fig. 8B).  The results demonstrate that 
CX3CL1 induces ICAM-1 surface expression on CD4+ T-cell in the presence Ag 
to a greater degree than in the presence of CX3CL1 or myelin Ag alone. 
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2.3.9 Supplementary text and figure description 
Supplementary Figure 2.1. Protein Arrays Demonstrate Differential 
Expression of Inflammatory Proteins in the CSF of RRMS Patients and HCs 
The prevailing approach to the simultaneous analysis of multiple protein 
expression levels is the two-dimensional polyacrylamide SDS page coupled with 
mass spectrometry [237].  However, the lack of quantitative measurements by 
this method limits its usefulness and broader application.  We approached the 
problem of biomarker identification by utilizing the RayBio Human Cytokine 
Antibody Array, a novel technology which was used to simultaneously analyze 
multiple protein levels in the CSF of RRMS patients and HCs.  120 cytokines, 
chemokines, growth factors and adhesion molecules were analyzed in the CSF of 
RRMS patients and HCs (Table S1).    
Of the 120 measured proteins, 13 were differentially expressed in CSF 
from  RRMS patients in comparison to HCs.  These proteins included four 
chemokines (CX3CL1, HCC-4, Eotaxin-2, GRO), 4 growth factors (FGF-6, PIGF, 
FGF-4, IGFBP-4) and 1 receptor tyrosine kinase that binds growth factors (Axl), 2 
cytokines (IL-3 and MIF), and 2 adhesion molecules (sICAM-1 and sICAM-3) 
(Fig. S1). 
 
Supplementary Figure 2.2. FGF-6 Levels are elevated in CSF of RRMS 
Patients in Comparison to HCs 
FGF-6 was the only growth factor found in the protein array to be 
increased in RRMS CSF vs. HC CSF (2.3-fold increase, p = 0.044) (Fig S2).  
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FGF-6 also showed the greatest fold change of the three proteins found to be 
increased in the CSF.  To confirm and quantify increased FGF-6 levels found in 
the cytokine array, FGF-6 concentrations were measured in the CSF from an 
independent cohort of 11 RRMS patients and 16 HCs using ELISA.  This 
confirmed that FGF-6 levels were higher in RRMS CSF than HC CSF (Fig. S2, 
3.7-fold increase, p = 0.0001). 
 
2.4 DISCUSSION 
In the present study we used protein array technology [234, 238, 239] to 
identify in an unbiased fashion a differential expression of cytokines, chemokines, 
and growth factors in the CSF from untreated RRMS patients in comparison to 
HCs (Fig. S1).  We found significantly elevated FGF-6, CX3CL1, and IL-3 levels 
in the CSF of untreated RRMS patients in comparison to HCs.  CX3CL1 was the 
only chemokine identified by protein array and confirmed by ELISA to be 
significantly increased in the CSF of RRMS patients in comparison to HCs, 
confirming previous studies [139, 233].  Elevated CX3CL1 levels in the CSF have 
recently been shown to attractCX3CR1+CD4+ T-cells into the CNS lesions of MS 
patients [139].  sICAM-1 was found by protein arrays and confirmed by ELISA to 
be decreased in the CSF of RRMS patients in comparison to HCs (Fig. 2.1C-D).  
sICAM-1 has been shown to interfere with the ICAM-1-LFA-1-mediated adhesion 
of PBMCs to cerebral endothelial cells in-vitro [189].  In this context, suppressed 
CSF sICAM-1 expression in MS patients may be interpreted as an indicator of an 
inflammatory mechanism in MS, by which decreased sICAM-1 enables 
transmigration of inflammatory leukocytes into the CNS. 
59 
 
The CX3CL1-induced increase in TNF-α and IFN-γ gene expression, and 
increased IFN-γ secretion in CD4+ T-cells derived from untreated RRMS patients 
but not HCs, suggests that increased CX3CL1 concentrations may play a role in 
the induction of proinflammatory cytokines in RRMS.  Fraticelli et al., has 
identified that CX3CL1 contributes to the Th1-cell migration, and amplification of 
polarized T-cell responses in Th1 mediated but not Th2 mediated disease [199]. 
Bullard et al., have recently found that CD4+ T-cells adoptively transferred 
from myelin MOG-immunized ICAM-1 null mice into wild type (WT) mice failed to 
induce EAE, providing evidence that ICAM-1 expression on T-cells is critical for 
EAE induction [111]. These result suggest that ICAM-1 expression on T-cells 
may be more critical for the development of MOG-induced EAE than ICAM-1 
expression on BBB endothelia and other ICAM-1-expressing cells [111].  The 
same group also reported that ICAM-1 expression on T-cells, but not on APCs, 
was critical for proliferation of MOG-sensitized T-cells.  This group has 
demonstrated that splenic ICAM-1 null T-cells secrete lower levels of pro-
inflammatory cytokines IFN-γ, IL-17, and TNF-α. Furthermore, they found that 
spinal cord T-cells from ICAM-1 null EAE mice produced lower levels of IFN-γ 
than from WT mice, indicating that ICAM-1 expression has a direct effect on 
proinflammatory cytokine production [111]. 
Recently, Broux et al. have found that CX3CR1 is a marker for CD4+CD28- 
T-cells, a cell subset that is expanded in MS patients [139].  This cell subset was 
characterized by increased expression of LFA-1, ICAM-1, and VLA-4 adhesion 
molecules in comparison to CD4+CD28+ T-cells.  In this study, MS patients 
exhibited higher levels of ICAM-1 on CD4+CD28-CX3CR1+ T-cells than healthy 
controls.  These cells were found to degranulate after anti-CD3 mAb stimulation, 
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and a small number of these cells degranulated after stimulation with myelin 
peptides MBP and MOG.  CD4+CD28- cells preferentially migrated toward 
CX3CL1 in-vitro [139].  Lastly, CD4+CX3CR1+ T-cells were found in active MS 
lesions, and the apoptotic maker cleaved caspase-3 was expressed by 
oligodendrocytes in close proximity to CD4+CX3CR1+ T-cells, indicating that 
these cells may contribute to the MS lesion formation by causing oligodendrocyte 
apoptosis [139].  Our finding that CX3CR1+CD4+ T-cells are enriched in the CSF 
derived from RRMS patients supports the above findings.  
Our finding that CX3CR1+ICAM-1+CD4+ T-cells are enriched in the CSF 
compared to the blood samples of RRMS patients, together with upregulation of 
ICAM-1 on CD4+ T-cells following their in-vitro migration against CX3CL1, 
indicates that CX3CR1 and ICAM-1 may play a role in the migration of CD4+ T-
cells through the BBB. Therefore, blockade of CX3CL1-CX3CR1 interaction may 
be a therapeutic approach in MS. 
While a role for CX3CL1 in ICAM-1 upregulation had not been previously 
studied in lymphocytes, CX3CL1 was reported to induce ICAM-1 expression in 
vascular endothelial cells via CX3CR1 and Jak2-Stat5 signaling[164].  We have 
demonstrated here for the first time that CX3CL1 increases ICAM-1 expression 
on CD4+ T-cells derived from RRMS patients. Furthermore, in myelin peptide-
specific CD4+ T-cell lines, CX3CL1 in addition to myelin peptide increased ICAM-
1 expression in comparison to the stimulation with myelin Ag or CX3CL1 alone.  
Future studies will focus on characterization of signaling pathways involved in the 
CX3CL1-induced increase in ICAM-1 expression in lymphocytes.  
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Targeting CX3CL1-CX3CR1 interactions is currently a potential 
therapeutic approach for several diseases [167, 240, 241].  In RRMS, it may be 
the case that the overarching role for CX3CL1-CX3CR1 interactions is that of 
recruitment of inflammatory cells into the CNS —however, it would still be 
important to demonstrate whether this recruitment mostly involves inflammatory 
lymphocyte subsets that exacerbate disease, or rather lymphocytes and NK-cells 
that have immunoregulatory effects.  Secondly, given the different roles of 
membrane bound and soluble CX3CL1, it will be important to uncover whether 
modulation of these distinct CX3CL1 molecules differentially affects the 
immunopathogenesis of MS.   
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Figure 2.1. CX3CL1 is increased in CSF and sICAM-1 is decreased in the CSF of RRMS patients in 
comparison to HCs. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1. CX3CL1 is increased and sICAM-1 is decreased in the CSF of 
RRMS patients in comparison to HCs. A. 10 RRMS and 19 HC CSF samples 
were tested for the expression of 120 cytokine, chemokine, and growth factor 
proteins using protein array. B. CX3CL1 protein levels were measured in 18 
RRMS and 15 HC CSF samples, using ELISA. C. Relative protein expression of 
sICAM-1 was determined in 10 RRMS and 19 HC CSF samples using protein 
array. D. sICAM-1 protein concentration was determined in 18 RRMS and 15 HC 
CSF samples using ELISA.  For the cytokine array, relative protein expression is 
expressed in arbitrary units (AU). AU = Average of Normalized Density of 
Duplicates / Sum of normalized density of all protein spots on a single membrane. 
Statistical analysis was performed using unpaired t-tests.  *p < 0.05 ** p < 0.01. 
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Figure 2.2.CX3CL1 induces gene expression of IFN-γ and TNF-, and protein secretion of IFN-γ 
by CD4+T-cells derived from RRMS patients. 
  
Figure 2.2. CX3CL1 induces gene expression of IFN-γ and TNF-
secretion of IFN-γ by CD4+T-cells derived from RRMS patients. A. 1 x 106CD4+ 
T cells isolated from 6 RRMS patients and 7 HCs were cultured in the absence or 
presence of 1 ng/ml CX3CL1 for 6 h. RNA was isolated and cDNA was 
synthesized. qRT-PCR was performed for indicated cytokines B. 1 x 106CD4+ T-
cells isolated from 6 untreated RRMS patients and 6 HCs were cultured in the 
absence or presence of 1 ng/ml CX3CL1 for 48 h. Supernatants were collected and 
ELISAs were performed for measurements of IFN-γ secretion. Statistical analysis 
was performed using ANOVA. * = p < 0.05. ** p< 0.01. 
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Figure 2.3. The percentage of CX3CR1+CD4+T-cells is increased in blood-derived CD4+ cells from 
RRMS patients in comparison to HCs. 
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Figure 2.3.The percentage of CX3CR1+CD4+ T cells is increased in blood 
samples from RRMS patients in comparison to HCs. PBMCs derived from 9 
RRMS patients and 10 HCs were stained with fluorescently-labeled A.CD4 (8 
RRMS, 10 HC), B.CD8 (8 RRMS, 10 HC), C.CD19 (8 RRMS, 8 HC) mAbs, and 
D.CD14 (7 RRMS and 7 HC) mAb for gating, and co-stained for CCR1, CCR2, 
CCR3, CCR5, CCR6, and CX3CR1. The results are expressed as a percentage of 
gated cells expressing the chemokine receptor of interest. Statistical analysis was 
performed using unpaired t-tests. * p< 0.05. 
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Figure 2.4. ICAM-1+CD4+ T and ICAM-1+CD8+T-cells are increased in blood derived from 
untreated RRMS patients compared with HC blood. 
Figure 2.4. The percentage of ICAM-1+CD4+ T and ICAM-1+CD8+ T cells is 
increased in blood samples from RRMS patients in comparison to HCs.  
PBMCs derived from 9 RRMS patients and 10 HCs were stained with 
fluorescently-labeled A.CD4 (8 RRMS, 10 HC), B.CD8 (8 RRMS, 10 HC), 
C.CD19 (8 RRMS, 8 HC) mAbs, and D.CD14 (7 RRMS and 7 HC) mAb for 
gating, and co-stained for ICAM, VLA-4, and LFA-1. The PBMCs were then 
analyzed for expression of these adhesion molecules via flow cytometry. 
Statistical analysis was performed using unpaired t-tests. * p< 0.05, ***p < 
0.001. 
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Figure 2.5.The percentage of CX3CR1+ICAM-1+CD4+ T lymphocytes is increased in RRMS 
patients-derived CSF in comparison to corresponding blood samples. 
 
 
 
  
Figure 2.5. The expression of CX3CR1 and ICAM-1 is increased in both 
CD4+ and CD8+ T cells from CSF in comparison to the corresponding 
blood samples from RRMS patients. A. Surface expression of CX3CR1 and 
ICAM-1 was measured on CD4+ T cells derived from the CSF and 
corresponding blood samples of 8 RRMS patients. B. Surface expression of 
CX3CR1 and ICAM-1 was measured on CD8+ T cells derived from the CSF 
and corresponding blood samples of 7 RRMS patients.  Samples in (A) and (B) 
were evaluated for percentage of cells expressing CX3CR1 and ICAM-1, and 
mean fluorescence intensity (MFI) was used to quantify the mean level of 
CX3CR1 and ICAM-1 surface expression per cell. Statistical analysis was 
performed using paired t-tests. p< 0.05, ** p < 0.01, ***p < 0.001. 
 
B. 
A. 
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Figure 2.6. ICAM-1 is expressed on a higher percentage of CD4+T-cells which have migrated 
toward CX3CL1 than on the non-migrated cells. 
  
Figure 2.6. ICAM-1 expression increases on CD4+ T-cells that migrate 
toward CX3CL1. A. CD4+ T-cells migrate in a dose-dependent fashion 
against the CX3CL1 gradient.A.CD4+ and CD8+ T-cells (5x105 per condition) 
derived from 4 RRMS patients were used for a migration experiments against 
ascending concentrations of CX3CL1 over 4 h in a chemotactic chamber.  Data 
are presented as chemotactic index (CI), calculated as total cells migrated toward 
CX3CL1 / total cells migrated in the absence of CX3CL1.  B. A higher percentage 
of migrated CD4+T-cells express ICAM-1 in comparison to non-migrated cells 
from both RRMS patients and HCs.  5x105 separated CD4+T-cells per experiment 
from 4 MS patients and 4 HCs were used in migration experiments against 1 
ng/ml of CX3CL1 for 18 h in a chemotactic chamber. ICAM-1 surface levels were 
assessed on CD4+ T-cells and CD4+CX3CR1+ T-cells via flow cytometry. 
Statistical analysis was performed using paired t-tests. * p< 0.05, ** p < 0.01, ***p 
< 0.001. 
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Figure 2.7.CX3CL1 induces ICAM-1 expression on CD4+ T-cells derived from RRMS patients. 
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Figure 2.7. CX3CL1 induces ICAM-1 expression on a higher percentage of 
CD4+T-lymphocytes derived from RRMS patients in comparison to HCs. 
1x106/ml PBMCs derived from 6 RRMS patients and 7 HCs were cultured in 
the absence or presence of 1 ng/ml CX3CL1 for 48 h, stained and analyzed via 
flow cytometry to determine the percentages of CD4+T-cells that express 
ICAM-1. Statistical analysis was performed using ANOVA. * = p < 0.05. ** = p 
< 0.01. *** = p < 0.001. 
 
 
B1. 
C. 
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Figure 2.8.CX3CL1 upregulates ICAM-1 on myelin-antigen-specific CD4+ T-cells. 
 
  
Figure 2.8.CX3CL1 upregulates ICAM-1 on myelin-antigen-
specific CD4+ T cells. Three myelin-peptide specific CD4+ T cell lines 
were co-cultured with EBV-transformed B cells in the absence or 
presence of CX3CL1, myelin peptide antigen (PLP 180-199 or MBP 83-99) 
or control FLU-HA 306-318 antigen (48 h). Cells were stained and 
analyzed via flow cytometry to determine the intensity of ICAM-1 
expression on CD4+T cells.  CD4+ T cells were co-incubated 1:1 with 
irradiated EBV-transformed B cells (48 h), immunostained and 
analyzed by flow cytometry. B. Representative histogram of one out of 
three experiments.  Statistical analysis was performed using ANOVA, 
* = p < 0.05. 
  
CHAPTER 3 
CONCLUSIONS AND FUTURE DIRECTION 
3.1 CONCLUSIONS 
Two of the most important goals of MS research are (1) the development 
of a diagnostic biomarker, and (2) the development of new therapeutics to more 
effectively treat MS.  
The founding goal of this study was to identify proteins in the CSF during 
the initial acute stage of RRMS that might serve as biomarkers of early 
inflammatory response in MS.  To meet this goal, we utilized recently-developed 
protein array technology to perform an unbiased screen of cytokine, chemokine, 
and neurotrophic factors in the CSF derived from patients with RRMS compared 
to HCs.  This allowed us to profile CSF inflammatory proteins in RRMS.  CX3CL1 
was the only chemokine found by protein array—and subsequently confirmed by 
ELISA in a separate cohort—to be significantly increased in the CSF of RRMS 
patients in comparison to HCs.  This indicated to us that CX3CL1 is constitutively 
produced in the CSF of healthy individuals, but this production increases during 
RRMS. 
While we found the increase of CX3CL1 in CSF to be interesting for the 
purposes of studying RRMS immunopathogenesis, it would be difficult to validate 
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CX3CL1 as a biomarker for RRMS for two reasons.  First, given that CX3CL1 is 
upregulated in other CNS inflammatory disorders [233], a finding of increased 
levels of CX3CL1 in the CSF of a single patient would not rule out the possibility 
of another inflammatory disease.  Second, while we found CX3CL1 to be 
increased significantly in the CSF of RRMS patients compared to HCs, a subset 
of RRMS patients expressed CX3CL1 at comparable levels to HCs.   Therefore, 
these constraints reflecting suboptimal specificity and sensitivity of CX3CL1, 
would make analysis of CSF levels of CX3CL1 alone an imperfect biomarker for 
RRMS.  However, it should be noted that CX3CL1 may have the potential to be 
analyzed for the purposes of diagnosis in a panel with other chemokines, 
cytokines, and adhesion molecules. 
Another relevant finding from the CSF cytokine array was that sICAM-1 
levels are diminished in the CSF derived from untreated RRMS patients 
compared to HCs.  This finding was confirmed by ELISA in a separate cohort of 
patients.  Because sICAM-1 competes with ICAM-1 to bind LFA-1, it has been 
speculated that it might play disease-attenuating role in MS [188-190].  sICAM-1 
binds LFA-1 on inflammatory lymphocytes, thus ablating LFA-1 interactions with 
BBB endothelial ICAM-1, and therefore may reduce lymphocyte migration into the 
CNS during MS [190].   
We found that CX3CR1 upregulates IFN-γ and TNF-α gene expression.  
We also found that CX3CL1 increases secretion of IFN-γ in CD4+ T-cells derived 
from RRMS patients but not HCs.  This suggests that increased CX3CL1 
concentrations play a role in the production of proinflammatory cytokines during 
RRMS.  This data is especially relevant in light of a study by Fraticelli and 
colleagues that has identified CX3CL1 as a contributor to Th1 polarization and 
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migration, and amplification of polarized T-cell responses in Th1-mediated but not 
Th2-mediated diseases [199].  Taken together, these data suggest that CX3CL1 
may be part of an inflammatory positive feedback loop with IFN-γ and TNF-αthat 
is prevalent during Th1-mediated diseases such as MS. 
We found that CX3CR1 is expressed on a greater percentage of CD4+ T-
cells derived from RRMS patients in comparison to HCs.  This led us to speculate 
that CX3CR1 may be upregulated due to increased concentrations of CX3CL1, 
which may represent an immunopathological aspect of the disease.  An 
upregulation of CX3CR1 on CD4+ T-cells during RRMS may increase migratory 
ability of these cells, and their BBB transmigration. 
We found that CCR5 is expressed on a greater percentage of CD8+ T-cells 
derived from RRMS patients compared to HCs.  CCR5 is a receptor for CCL3, 
CCL4, CCL5, CCL8, and CCL14, and has been previously implicated in MS 
pathogenesis [98].  Interestingly, Kivisakk, et al., recently showed that CCR5 is 
increased on blood-derived CD8+ T-cells after natalizumab treatment compared 
to untreated patients [107].  The authors conclude that the increase in percentage 
of CD8+ T-cells expressing CCR5 may be due to sequestration of activated cells 
in the blood due to blockade of BBB transmigration via natalizumab[107].  
Interestingly, Eikelenboom, et al., found that CCR5 expression on CD8+ T-cells is 
correlated with T2, but not T1 lesion load, in MS patients [176].  Our findings 
suggest that upregulation of CCR5 on CD8+T-cells may be one mechanism by 
which CD8+T-cells increase their ability to migrate toward the CNS during RRMS 
pathogenesis. 
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We found that a greater percentage of CD4+T-cells and CD8+T-cells 
derived from untreated RRMS patients express ICAM-1 compared to CD4+T-cells 
derived from HCs.  This increase in the percentage of T-cells that express ICAM-
1 during RRMS suggests that ICAM-1 may play a role in RRMS pathogenesis, 
perhaps by increasing the chemotactic ability of CD4+ and CD8+T-cells that 
migrate into the CNS to cause lesion formation and tissue damage.  In Bullard, et 
al., 2007, T lymphocyte adoptive transfer experiments from myelin 
oligodendrocyte glycoprotein (MOG)-sensitized ICAM-1 null mice into wild type 
(WT) mice failed to induce EAE, providing evidence that ICAM-1 expression on 
T-cells is critical for EAE pathogenesis.  The authors observed lower levels of 
clinical symptoms as well as a lower percentage of mice exhibiting any clinical 
signs of disease in ICAM-1 null T cell transfers > WT than in WT T cell transfers > 
ICAM-1 null mice or the WT > WT internal controls.  This implies that the 
expression of ICAM-1 on T-cells is more critical for the development of MOG-
induced EAE than the expression of ICAM-1 on BBB endothelia and all other 
ICAM-1-expressing cells [111]. 
We find that CX3CR1+ICAM-1+CD4+T-cells make up a significantly greater 
proportion of CD4+T-cells derived from the CSF than do CX3CR1+ICAM-
1+CD4+T-cells derived from the blood of RRMS patients.  This suggests that 
either this subset of CD4+T-cells migrates into the CNS more effectively during 
RRMS, or that CX3CR1 and ICAM-1 are upregulated on CD4+T-cells after 
migration into the CNS during RRMS pathogenesis.  In vivo migration assays 
uncovered that CX3CR1+ICAM-1+CD4+T-cells preferentially migrate toward 
CX3CL1.  
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Our study uncovers that upregulation of ICAM-1 via CX3CL1 occurs in 
CD4+ T lymphocytes, and is magnified in CD4+ T lymphocytes derived from 
RRMS patients or stimulated with either PLP or MBP peptide.  These data 
indicate that CX3CL1 induced upregulation of ICAM-1 on CD4+ T lymphocytes 
may represent a previously unrecognized aspect of RRMS pathology.  While a 
role for CX3CL1 in ICAM-1 upregulation had not previously been studied in 
leukocytes, CX3CL1 was shown to upregulate ICAM-1 in vascular endothelial 
cells via CX3CR1 and Jak2-Stat5 signaling[164].  Levels of phosphorylated Jak2 
and Stat5 were increased in sequential order within 30 minutes of exposure to 
CX3CL1; this effect was blocked by transfection of CX3CR1 siRNA [164].   
CX3CL1-CX3CR1 interactions play roles in several inflammatory diseases 
and animal disease models and are therefore currently the focus of attention as a 
potential therapeutic target for a number of illnesses [167, 240].  As roles for 
CX3CL1-CX3CR1 interactions in MS have not been comprehensively studied, it 
is difficult to predict how various types of modulation of this chemokine-receptor 
duo and the interacting network of related molecules may affect MS pathology.  It 
may be the case that the overarching role for CX3CL1-CX3CR1 interactions is 
simply that of recruitment of immune cells into the CNS during MS—however, if 
this is the case, it would still be important to uncover whether this recruitment 
mostly involves inflammatory leukocyte subsets that exacerbate disease 
condition, or rather leukocytes that function in immunosuppressive and 
neuroprotective roles.  Secondly, given the different role of membrane bound and 
soluble CX3CL1, it will be important to uncover whether upregulation and 
downregulation of these distinct chemokines have synergistic or opposing effects 
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on disease state.  Overall, a great deal of work is left unfinished regarding roles 
for CX3CL1-CX3CR1 in MS pathology. 
3.2 Future Directions 
 Several results generated by our findings in this dissertation compel us to 
further investigate roles for CX3CL1, CX3CR1, ICAM-1, and related molecules in 
MS immunopathogenesis.  The finding that CX3CL1 upregulates ICAM-1 on 
CD4+T-cells in the presence of PBMCs derived from untreated RRMS patients, 
paired with the finding that CX3CL1 upregulates ICAM-1 on myelin-Ag-specific 
CD4+T-cells in the presence of EBV-transformed B cells, presents the possibility 
that CX3CL1 upregulation of ICAM-1 requires other cell subsets for upregulation 
of ICAM-1 in CD4+ cells. Co-culture of isolated CD4+T-cells with candidate APCs 
such as monocytes and B cells in the absence or presence of CX3CL1, 
compared to isolated CD4+ T cell culture, followed by quantitation of surface 
ICAM-1 on CD4+T-cells via flow cytometry, will answer which cell subsets or 
secreted soluble factors are critical for CX3CL1-induced expression of ICAM-1 on 
CD4+T-cells. 
 It would be important to elucidate which intracellular pathway or pathways 
are responsible for the upregulation of ICAM-1 via CX3CL1.  CX3CL1 has been 
shown to upregulate ICAM-1 via signaling through CX3CR1 in HUVECs, which 
increases phosphorylation of JAK2 and STAT5 [164].  An intracellular pathway 
mediating ICAM-1 upregulation via CX3CL1 has not yet been identified in CD4+T-
cells.  If CX3CR1 is directly involved in the upregulation of ICAM-1 in CX3CL1-
stimulated CD4+T-cells, we would expect that transfection with CX3CR1-
interfering RNA, would decrease levels of ICAM-1 as measured by Western blot 
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or flow cytometry analysis.  To establish that JAK2 and STAT5 phosphorylation 
are necessary for fractalkine-induced ICAM-1 upregulation, we would expect that 
incubation with CX3CL1, followed by analysis of phosphorylated JAK2 and 
STAT5 via Western blot or flow cytometry, would show an increase in JAK2 and 
STAT5 phosphorylation, and that this increase would be ablated by JAK2 and 
STAT5 siRNA.   
 Our findings that IFN-γ and TNF-α transcripts, and IFN-γ protein secretion 
are increased in the presence of CX3CL1 in CD4+T-cells derived from RRMS 
patients but not HCs indicates that CX3CL1 may upregulate proinflammatory 
cytokines in CD4+T-cells during inflammation.  This data is interesting in the 
context of study by Fraticelli, et al., who showed that IFN-γ and TNF-α induce 
CX3CL1 expression and release by endothelium, and CX3CL1 expression is 
increased in the IFN- γ-mediated Th1 disease psoriasis, but is not upregulated in 
Th2-dominated atopic dermatitis.  In this context, upregulation of IFN-γ and TNF-
α via CX3CL1 in MS may represent an amplified Th1 response.  It would be 
interesting to test this hypothesis by incubating PBMC cultures with IFN-γ and 
TNF-α, followed by quantitation of CX3CL1 levels in the supernatant via ELISA. 
 Our finding that CX3CR1+ICAM-1+CD4+T-cells are both increased in 
percentage of cells and in per-cell expression of CX3CR1 and ICAM-1 in RRMS-
derived CSF compared to blood suggests that these cells may preferentially 
migrate into the CNS during RRMS.  To address this issue further, it would be 
informative to immunostain acute MS lesions for evidence that CX3CR1+ICAM-
1+CD4+T-cells are present at the site of tissue damage in MS.   
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We hypothesized that increased CX3CL1-CX3CR1 interactions upregulate 
ICAM-1 and IFN-γ in CD4+T-cells, and that CX3CR1+ICAM-1+CD4+T-cells are 
enriched in the CSF during RRMS. The present study has identified an increase 
in CX3CL1, and a decrease in sICAM-1 in the CSF of RRMS patients compared 
to HCs, and has shown an increase in the percentage of CX3CR1+ICAM-
1+CD4+T-cells derived from CSF compared to blood of early untreated RRMS 
patients.  CX3CL1 increased IFN-γ gene expression and protein secretion in 
RRMS-derived but not HC-derived CD4+T-cells.  CX3CL1 was found to 
upregulate ICAM-1 on the surface of RRMS-patient-derived but not HC-derived 
CD4+T-cells, and on stimulated myelin-antigen-specific CD4+ T cell lines.  These 
results indicate that CX3CL1 may play a pathological role in RRMS by enhancing 
migration of IFN-γ-secreting CX3CR1+ICAM-1+CD4+T-cells into the CNS. 
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Supplementary Text: Protein array analysis 
In our initial CSF screen, we identified 13 proteins which were differentially 
expressed between RRMS and HC CSF.  Interestingly, only three of these 13 
proteins were found to be expressed at higher levels in RRMS CSF; the 
remaining 10 were decreased.  The following is a brief description of each protein 
found to be increased or decreased in the CSF of untreated RRMS patients 
compared to HCs. 
Proteins increased in the CSF of untreated RRMS patients 
Trophic factor: FGF-6 
We found FGF-6 expression to be 2.3-fold higher in the CSF derived from 
RRMS patients compared to the CSF from HCs (p = 0.44 please check in figure 
p<0.05).  To our knowledge, FGF-6 has not been previously found to be 
expressed at elevated levels in the CSF of MS patients, nor has it been found to 
play a role in MS pathogenesis.  However, elevated levels of the closely-related 
growth factor FGF-2 have been found in the CSF of RRMS patients [242], and 
FGF-2 has been shown to have a potential neuroprotective role in active MS 
lesions [243].  Studies in mouse models of demyelination have suggested that 
FGF-2 may play a role in the remyelination that occurs in active lesions by 
directing oligodendrocyte stimulating[244]. 
Cytokine: IL-3 
We found IL-3 expression to be 1.8 fold higher in the CSF derived from 
RRMS patients when compared to the CSF derived from HCs (p = 0.005). IL-3 
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has previously been found to be upregulated in MS lesions [235]. Furthermore, 
IL-3 has been shown to induce activation of the JAK2-STAT5 pathway in 
microglia, leading to microglial proliferation, expression of CD40, and expression 
of MHCII [245].  Therefore, increased levels of IL-3 in the CSF may reflect 
microglial activation and antigen presentation during early MS.  Recently, a role 
for IL-3-stimulated plasmacytoid (p)DCs derived from RRMS patients were shown 
to exhibit delayed maturation and diminished secretion of IFN-α/β compared to 
pDCs derived from HCs.  This diminished pDC function in MS may have 
immunopathological consequences, as pDCs have immunoregulatory properties 
that may limit MS pathology by stimulation of regulatory T-cells[246].  As CX3CL1 
has been found to upregulate ICAM-1 via the JAK2-STAT5 pathway [164], it 
would be interesting to investigate whether upregulation of IL-3 can also be 
induced by CX3CL1 in microglia, pDCs, or other immune cell subsets. 
Chemokine: CX3CL1 
In this study, CX3CL1 was found to be expressed at significantly higher 
levels in the CSF of RRMS patients compared to HCs (2.0 fold increase, p = 
0.01).  These data confirm an earlier report that CX3CL1 expression is increased 
in CSF derived from patients with RRMS and other neuroinflammatory disorders 
[233].   
 
 
 
80 
 
Proteins decreased in the CSF of untreated RRMS patients 
Proinflammatory cytokine: MIF 
We found Macrophage migration inhibitory factor (MIF) to be 
downregulated 1.7 fold in the CSF of untreated RRMS patients compared to the 
CSF of HCs (p = 0.05).  MIF is a proinflammatory cytokine and inhibitor of 
macrophage trafficking that is secreted by macrophages and activated T-cells.  It 
has previously been shown to be expressed at elevated levels in the CSF of 
relapsing MS patients [208].  Recently, a small molecule inhibitor of MIF has 
been shown to reduce the clinical manifestations of EAE, as well as the total 
number of relapses, potentially by inhibiting lymphocyte migration into the CNS 
[247].  In this context, our finding that MIF is significantly decreased in early MS 
can be interpreted as an indication that that ability of MIF to inhibit macrophage 
migration is diminished in early RRMS, potentially suggesting that blockade of 
MIF early in RRMS could be one mechanism of pathogenesis by which 
macrophages are able to migrate more freely toward active lesions. 
Chemokines: HCC-4, Eotaxin-2 
HCC-4 is downregulated 1.9 -old in the CSF of untreated RRMS patients 
compared to the CSF of HCs (p = 0.020).   HCC-4 is a chemokine which binds to 
CCR1 and CCR2 on lymphocytes and monocytes.  HCC-4 has not previously 
been shown to play a role in MS.  However, CCR1 and CCR2 have both been 
implicated in EAE and MS. 
Eotaxin-2 is downregulated 2.1-fold in the CSF of RRMS patients 
compared to the CSF of HCs (p = 0.043).   Eotaxin-2 binds to CCR3 and has 
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traditionally been characterized as an eosinophil chemoattractant.  CCR3 is 
expressed on macrophages in MS lesions, but otherwise has not been studied in 
MS [218]. Eotaxin-2 was recently found to be expressed at significantly higher 
levels in NMO CSF compared to RRMS or PPMS CSF [248].   
We found growth-regulated oncogene (GRO) to be downregulated 4.4-fold 
in the CSF of untreated RRMS patients compared to the CSF of HCs (p = 0.016).   
GRO is a chemoattractive protein produced by astrocytes that binds CXCR2 on 
oligodendrocytes. Diminished GRO concentration indicates a suppression of 
oligodendrocyte progenitor cell (OPC) migration into demyelinated areas in EAE 
[249].  It is especially interesting that GRO is downregulated in early RRMS, 
because in the cuprizone model of demyelination and remyelination, NG2+ OPCs 
migrate into demyelinated corpus callosum as early as two weeks after first toxic 
insult  [250].  It is plausible that in early RRMS, downregulation of GRO may 
represent a mechanism of damage, or suppression of repair, as OPCs may be 
prohibited from localizing to lesions to remyelinate damaged axons.   
Trophic factors: PIGF, FGF-4, and IGFBP-4 
We found Placental Growth Factor (PIGF) to be downregulated 1.8 fold in 
the CSF of untreated RRMS patients compared to the CSF of HCs (p = 0.048).    
PIGF is a trophic factor and a member of the vascular endothelial growth factor 
(VEGF) family that is a ligand for two receptors: VEGFR-1 and neuropilins.  PIGF 
has generally been studied in the context of its roles in angiogenesis.  PIGF can 
be considered proinflammatory because it is a known chemoattractant of 
monocytes and a stimulator of proinflammatory cytokine secretion [251], but it 
also has known neurotrophic properties in several animal models of the central 
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nervous system disease [252].  Thus a reduction in PIGF expression in the CSF 
in RRMS can be interpreted as an inhibition of monocyte chemotaxis as well as 
inhibition of neuroprotection. 
We found fibroblast growth factor 4 (FGF-4) to be downregulated 3.0 fold 
in the CSF of untreated RRMS patients compared to the CSF of HCs (p = 0.039). 
While no information is currently available regarding potential roles for FGF-4 in 
MS, CSF derived from RRMS patients has been reported to contain increased 
levels of FGF-2 [242].  Furthermore, FGF-2 plays a potential neuroprotective role 
in active MS lesions, leading us to speculate that FGF-4 may play a similar role 
[243].  FGF-2 has also been shown in mice to direct oligodendrocyte 
differentiation in active lesions, thus playing a potential role in remyelination. 
[244].  Taken together, if FGF-4 functions in a similar manner as FGF-2, then the 
decrease in FGF-4 in CSF may be interpreted as contributing to a diminished 
capacity for remyelination.   
 Insulin-like growth factor-4 (IGFBP-4) is downregulated 6.8-fold in RRMS 
CSF compared to HC CSF (p = 0.02).  IGFBP-4 binds IGF-I to inhibit cellular 
growth, differentiation, and survival of brain-derived endothelia and other cell 
subsets.  To our knowledge, IGFBP-4 has not been studied in MS.  It is primarily 
known as an anti-angiogenic factor in glioblastomas and a promising therapy for 
glioblastoma[253].  In the context of IGFBP-4 primarily acting as an inhibitor of 
endothelial growth and survival, downregulation of IGFBP-4 in early MS CSF may 
allow the survival in endothelia of the BBB, and may therefore be interpreted as a 
part of a potential MS BBB repair mechanism. 
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Adhesion molecules: sICAM-1 and sICAM-3 
sICAM-1 is downregulated 5.6-fold in the CSF of untreated RRMS patients 
compared to the CSF of HCs (p = 0.005).  sICAM-1 lacks the transmembrane 
and cytoplasmic regions of ICAM-1 and is produced by many cell types, including 
endothelia and leukocytes.  sICAM-1 binds competitively to ICAM-1 ligands 
including LFA-1, and therefore has a therapeutic potential.  Interestingly, in vitro 
application of sICAM-1 to activated lymphocytes blocks their adhesion to CNS-
derived endothelial cells, and this effect is abrogated in a dose-dependent 
manner upon application of anti-ICAM antibody [189]. 
Soluble (s)ICAM-3 is downregulated 1.9-fold in the CSF of RRMS patients 
compared to the CSF of HCs (p = 0.018).  ICAM-3 is a ligand for LFA-1 that 
competes with ICAM-1 and ICAM-2.  ICAM-3 has been previously been shown to 
be upregulated in MS serum [254].  Kraus and colleagues found that the numbers 
of CD45RA+ICAM-3+ cells in the CSF of relapsing patients was higher than in 
patients in remission [255].  Since sICAM-3 most likely acts to competitively 
inhibit interactions between membrane bound ICAMs and LFA-1, sICAM-3 may 
be considered as an inhibitor of immune cell transmigration in MS.  Therefore, 
depressed levels of sICAM-3 may be interpreted as having a proinflammatory 
effect in MS and may therefore be considered a potential therapeutic target. 
Soluble Receptor Tyrosine Kinase: Axl 
Axl is downregulated 4.2 fold in the CSF of untreated RRMS patients 
compared to the CSF of HCs (p = 0.047).  Axl is one of the three receptor 
tyrosine kinases (Mertk and Tyro3) that constitute the TAM family of Tyrosine 
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kinases.  Axl binds to Growth arrest-specific protein 6 (Gas-6).  Weinger et al 
(2011) recently found that when Axl-/- mice were subjected to MOG-induced EAE, 
disease severity was greater than in WT mice, suggesting that Axl alleviates EAE 
progression [256].  We find Axl to be diminished in early MS, during the 
inflammatory stage of the disease, thus suggesting that decreased Axl 
expression may contribute to MS pathology.  In MS lesions, however, Axl has 
been shown to be upregulated, which seems to contradict our data [151].  
However, because we analyzed CSF in early MS, while Weinger and colleagues 
analyzed Axl expression in lesion tissue derived from chronic MS patients, it may 
be that while Axl expression is suppressed in the early, inflammatory stage of 
MS, it is upregulated at later time point in lesions as part of a repair mechanism.  
This discrepancy could be resolved by (a) immunostaining lesion tissue from MS 
patients near the time of diagnosis and (b) evaluating the CSF of MS patients 
later in disease. 
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Supplementary Figure S1. Protein array determined the differential expression of 
inflammatory proteins in the CSF of RRMS patients and HCs 
  
Figure S1. Differential expression of cytokines, chemokines, and growth 
factors in the CSF derived from RRMS patients compared to HCs. Ray 
Biotech cytokine array was utilized to reveal changes in CSF protein levels in 
RRMS patients compared to HCs.  10 RRMS CSF and 19 HC CSF samples 
were tested for expression of 120 cytokines, chemokines, and growth factors.  
Graph shows differential protein expression in the CSF from RRMS patients and 
HCs. Arbitrary units (AU) = Average of Normalized Density of Duplicates / Sum of 
normalized density of all protein spots in single membrane * p < 0.05. ** p < 0.01. 
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Supplementary figure 2. FGF-6 is elevated in CSF of RRMS patients in comparison to HCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Figure S2. FGF-6 is elevated in CSF of RRMS patients in 
comparison to HCs. A. 10 RRMS and 19 HC CSF samples were 
tested for the expression of 120 cytokine, chemokine, and growth 
factor proteins using protein array. B.FGF-6 protein levels were 
measured in 11 RRMS and 16 HC CSF samples, using ELISA.  For the 
cytokine array, relative protein expression is expressed in arbitrary 
units (AU). AU = Average of Normalized Density of Duplicates / Sum of 
normalized density of all protein spots on a single membrane. 
Statistical analysis was performed using unpaired t-tests.  ** = p < 0.01. 
*** = p < 0.001.  
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